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ABSTRACT 
 
Lipid movement in cells occurs by a variety of methods. Lipids diffuse freely 
along the lateral plane of a membrane and can translocate between the lipid 
leaflets, either spontaneously or with the help of enzymes. Lipid translocation 
between the different cellular compartments predominantly takes place 
through vesicular transport. Specialized lipid transport proteins (LTPs) have 
also emerged as important players in lipid movement, as well as other cellular 
processes. 
 
In this thesis we have studied the glycolipid transport protein (GLTP), a 
protein that transports glycosphingolipids (GSLs). While the in vitro 
properties of GLTP have been well characterized, its cell biological role 
remains elusive. By altering GSL and GLTP levels in cells, we have extracted 
clues towards the protein's function. Based on the results presented in this 
thesis and in previous works, we hypothesize that GLTP is involved in the 
GSL homeostasis in cells. GLTP most likely functions as a transporter or 
sensor of newly synthesized glucosylceramide (GlcCer), at or near the site of 
GlcCer synthesis. GLTP also seems to be involved in the synthesis of 
globotriacylceramide, perhaps in a manner that is similar to that of the four-
phosphate adaptor protein 2, another GlcCer-transporting LTP. 
 
Additionally, we have developed and studied a novel method of introducing 
ceramides to cells, using a solvent-free approach. Ceramides are important 
lipids that are implicated in several cellular functions. Their role as pro-
apoptotic molecules is particularly evident. Ceramides form stable bilayer 
structures when complexed with cholesterol phosphocholine (CholPC), a 
large-headgroup sterol. By adding ceramide/CholPC complexes to the growth 
medium, various chain length ceramides were successfully delivered to cells 
in culture. The uptake rate was dependent on the chain length of the ceramide, 
where shorter lipids were internalized more quickly. The rate of uptake also 
determined how the cells metabolised the ceramides. Faster uptake favored 
conversion of ceramide to GlcCer, whereas slower delivery resulted mainly in 
breakdown of the lipid. 
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1. INTRODUCTION 
 
Lipids are a vast and diverse group of naturally occurring compounds that are 
generally characterized by their solubility in non-polar solvents. While, 
technically, a broad array of structurally unrelated molecules fall under this 
description, lipids are usually defined as fatty acids and their derivatives, as 
well as substances that are biosynthetically or functionally related to these 
compounds [1, 2]. Lipids, together with proteins, are major components in the 
membrane structures that enclose living cells, as well as in the membranes 
that capsulate the intracellular organelles. The biological membranes function 
as selectively permeable barriers that define enclosed spaces, in which cells 
maintain specific biochemical environments. Biological membranes, and the 
lipids and proteins that they contain, are involved in a variety of essential 
cellular processes. 
 
In cells, most of the novel synthesis of lipids takes place in the endoplasmatic 
reticulum (ER), from where the lipids subsequently can be transported to 
other organelles [3, 4]. Once translocated, the lipids either carry out their 
designated functions or are further modified to form more complex 
derivatives. As most lipids are hydrophobic in nature, their transport and 
translocation within cells rarely occurs as a spontaneous diffusion through the 
aqueous environment in the cytosol. Instead, cells employ a variety of 
alternative methods by which they transport lipids. The bulk trafficking of 
lipids takes place by vesicular transport, where lipids and proteins form 
cargo-enclosing, water-soluble structures that bud off from membranes and 
are subsequently directed and transported to their goal destinations [4, 5]. 
Lipids also diffuse through membranes laterally, or “flip-flop” from one side 
of a membrane to the other, either spontaneously or with the help of specific 
translocator enzymes [6, 7]. Lipids can also be transported with the help of 
lipid transfer proteins (LTPs). The LTPs are a group of specialized proteins 
that contain hydrophobic cavities in their fully folded structures, to which 
lipids can bind [8, 9]. LTPs are generally capable of mediating lipid monomer 
exchange between lipid membranes in vitro, however, this is not necessary 
the case in vivo. Some LTPs have been shown to mediate actual lipid transfer 
in cells, however, sensory and regulatory roles have also been suggested. 
Overall, the more specific, non-vesicular, protein-mediated method of lipid 
trafficking is crucial when it comes to maintaining proper cellular lipid 
homeostasis. An in-depth understanding of the hows and whys of these 
systems is therefore of great importance.  
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This thesis will focus on a specific LTP, namely the glycolipid transfer 
protein (GLTP), as well as its putative lipid interaction partners. GLTP has 
been shown to bind and mediate the transfer of various glycosphingolipids 
between model membranes, however, the precise biological role of GLTP is 
unknown [10]. The work presented in this thesis was performed in an effort to 
elaborate on the possible biological roles of GLTP, building on the hypothesis 
that GLTP is involved in the cellular glycosphingolipid homeostasis. In 
addition to this, a novel, solvent-free method of introducing ceramides to 
cultured cells has been explored, and its applicability in elucidating GLTP-
function is discussed. 
 
Following this introduction, the readers will be presented with a literature 
overview that lays a foundation for the various themes explored in the works 
presented in chapter 5. The author has attempted to describe most of the 
background literature in a brief and concise manner, however, more emphasis 
will be given to the GLTP-family of proteins, as well as their ligands and 
possible interaction partners. 
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2. REVIEW OF THE LITERATURE 
 
2.1 THE BIOMEMBRANE STRUCTURE 
 
Lipids have a variety of important roles in organisms. Their main functions 
include energy storage (mainly in the form of triacylglycerols and steryl-
esters), various signaling events in (or between) cells and serving as structural 
components in biological membranes. The chemical properties of lipids are 
essential for the formation of the barrier structures (i.e. biomembranes) that 
enclose all cells. Segregation of the outside environment from the 
intracellular space allows for the compartmentalization of the various 
chemical reactions that occur within cells and are essential for all life. 
Furthermore, cells also enclose their internal organelle structures with lipid 
barriers, allowing for a variety of chemical environments to simultaneously 
co-exist in a cell. These specialized subunits are responsible for distinct 
functions within the cell, such as sorting and trafficking events, cell 
respiration and the synthesis and degradation of various biomolecules. 
 
As early as 1925, it was proposed that biomembranes are made up of a bilayer 
structure, where two leaflets of amphiphilic lipids organize with their polar 
headgroup regions facing towards the aqueous surroundings [11]. With time, 
it became apparent that biomembranes also contain protein and carbohydrate 
components. In 1972, Singer and Nicolson proposed the fluid-mosaic model, 
which describes the biomembrane as a bilayer of lipids with embedded, 
integral and peripheral membrane proteins (see figure 1) [12]. The fluid-
mosaic model described the bilayer structure, more or less, as evenly 
dispersed in relation to its lipid and protein constituents. Additionally, the 
membrane lipids were considered to be somewhat static in nature, with more 
emphasis being given to the protein components, in respect to dynamic 
membrane functionality. In the decades following the proposal, the model has 
undergone significant revision. It is now believed that the cellular membranes 
are highly organized and dynamic assemblies, in terms of both their protein 
and lipid components. 
 
Over the years, evidence supporting the existence of membrane domains has 
also emerged [13]. These domains are proposed to be enriched in certain lipid 
species and proteins that putatively form small, short-lived lateral raft-like 
regions [14]. Membrane domains are implicated in several of the cellular 
processes that the membranes function as platforms for. This lateral 
organization of lipids will be discussed in more detail in section 2.3.2. 
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Figure 1. A simplified, schematic representation of the plasma membrane and some 
of its structural components. The image is adapted from Wikimedia Commons. 
Attribution: Timothy Gu / CC-BY-SA-3.0  
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2.2 THE BIOMEMBRANE LIPIDS 
 
Modern mass spectrometry (MS) and bioinformatic methodologies have 
revealed that cells contain thousands of structurally distinct lipid molecules 
[2]. Variations in the polar headgroups, as well as the hydrophobic acyl chain 
regions, give rise to this vast structural diversity. Therefore, in an effort of 
simplification, lipids are generally divided into several groups, as determined 
by common structural characteristics. The three main lipid groups that are 
found in mammalian biomembranes are the glycerophospholipids, the 
sphingolipids and the sterols. The structures and some of the characteristics of 
these main membrane lipids will be discussed below. 
 
2.2.1 Glycerophospholipids 
 
The glycerophospholipids are the most abundant lipid species in the 
mammalian cell, making up 50 – 60 mol% of all the cellular lipids [4]. Their 
main function is to serve as bulk structural components in biomembranes, 
however, glycerophospholipids also play a role in cellular signaling events, 
for example by functioning as precursors for lipid mediators [15]. Glycero-
phospholipids consist of a glycerol backbone with two fatty acid chains that 
are esterified to the sn-1 and sn-2 hydroxyl groups on the glycerol (figure 2). 
The sn-3 hydroxyl group is in turn coupled to a polar phosphate [16]. The 
phosphate can be further modified by the addition of various chemical groups. 
The most common modification is the addition of a choline, yielding 
phosphatidylcholine (PC). PC constitutes the bulk of the membrane glycero-
phospholipids in eukaryotic cells. Natural PC contains fatty acids that are 
usually between 16 and 18 carbon atoms in length. The sn-1 fatty acid is 
usually saturated, whereas the sn-2 fatty acid generally contains 1 to 6 cis-
double bonds [17]. Other typical glycerophospholipids include phosphatidyl-
glycerol (PG), phosphatidylethanolamine (PE), phosphatidylinositol (PI) and 
phosphatidylserine (PS).  
 
2.2.2 Sphingolipids 
 
Sphingolipids are not glycerol-based, but instead contain a long-chain 
aliphatic amino alcohol, a so-called sphingoid base. Sphingolipids generally 
make up about 10 mol% of the total lipids in mammalian cells [4]. One of the 
simplest sphingolipids is ceramide, which consists of a sphingosine and a 
fatty acid, linked together via an amide bond at the C2 position (figure 2). 
Ceramide has a small hydroxyl headgroup linked to the C3 position. In 
naturally occurring ceramide, the sphingosine base is usually 18 carbons long, 
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with a trans-double bond between carbons 4 and 5, whereas the acyl chain 
length can vary [18]. Ceramide is a central molecule in the sphingolipid 
metabolism, as it functions as a precursor for all higher sphingolipids [19]. 
Ceramide, and its many metabolites, have been implicated in several key 
cellular functions, including cell growth, signaling, proliferation, 
differentiation and apoptosis [20–26]. 
 
 
 
Figure 2. Molecular structures of some common biomembrane lipids. The numbers 
represent stereospecific numbering (sn) or carbon atom positions. The colored boxes 
indicate some of the building blocks of the various lipids, as described in the text.  
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Sphingomyelin (SM) is another sphingolipid with key cellular implications. 
SM is produced from ceramide by the addition of a phosphocholine 
headgroup. As such, the chain length and saturation of the sphingosine base 
and acyl chain depend on the precursor ceramide. In mammals, SM is 
generally the most prevalent of its lipid class and is located mainly to the 
extracellular leaflet of the plasma membrane (PM) [27]. SM makes up 2 – 
15% of the total phospholipid content, depending on tissue type [28]. SM is 
accumulated in neural tissue, where it plays a role as an insulator in the 
membranous myelin sheath that surrounds nerve cell axons. Additionally, SM 
has been implicated in signal transduction, as well as in apoptosis, through a 
hydrolysis pathway that generates ceramide [29, 30]. 
 
Glycosphingolipids (GSLs) are formed in a glycosylation process, where a 
carbohydrate moiety is attached to a ceramide. The simplest GSLs (the 
monohexosylceramides) are glucosylceramide (GlcCer) and galactosyl-
ceramide (GalCer), which contain a glucose and a galactose molecule, 
respectively. GlcCer functions as the precursor for most of the higher GSLs 
found in mammalian cells. The synthesis of higher GSLs takes place by 
stepwise addition of carbohydrate groups to respective precursors. Some 
higher GSLs may have up to 20 sugar residues in their headgroups [31]. GSLs 
are proposed to take part in many cellular processes, such as cell-cell 
interactions and various signaling events [32]. GalCer, similarly to SM, is a 
major component of the myelin sheath [33]. GSLs also serve as receptors for 
various bacterial toxins on the cell surface [32, 34]. As the ceramides and the 
GSLs are the most relevant lipids in this thesis, they will be discussed in 
greater detail in sections 2.5 and 2.6. 
 
2.2.3 Sterols 
 
The sterols, with their 4-ring molecular structure, look distinctly different 
from other biomembrane lipids. Different organisms make use of different 
sterols. Stigmasterol and sitosterol, for example, are found in plants, whereas 
ergosterol is found in yeast [35, 36]. The dominant sterol in vertebrates is 
cholesterol, which makes up roughly 25 mol% of the membrane lipids in cells 
[37]. Cholesterol contains a hydroxyl group on carbon 3, which acts as its 
polar headgroup (figure 2). Attached to carbon 17 is a short aliphatic chain. 
Cholesterol cannot form bilayers by itself, however, depending on the 
surrounding lipids and other environmental factors, it can have a stabilizing 
effect on the overall membrane fluidity [38]. In addition to being an important 
constituent in membranes, cholesterol also has regulatory roles in cells. 
Cholesterol functions as a precursor to vitamin D, the bile acids, as well as the 
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steroid hormones [39]. Cholesterol is also implicated in cell signaling and 
membrane trafficking events [40], as well as in many diseases, perhaps most 
notably atherosclerosis [41]. 
 
2.3 LIPID AGGREGATES 
 
Lipids demonstrate amphipathic properties, which means that they have both 
hydrophobic and hydrophilic parts. Due to these inherent attributes, lipids 
tend to spontaneously form aggregates with specific conformations when 
introduced to aqueous environments. The hydrophobic effect is the main 
driving force behind the formation of a lipid membrane structure. In 
accordance with the principle of minimum energy, when lipids are dispersed 
in aqueous solution, maximal entropy is preserved when the hydrophobic 
parts of the lipids (e.g. the fatty acid chains of glycerophospholipids) arrange 
to face each other, and the hydrophilic parts (e.g. the phosphate headgroups of 
glycerophospholipids) face the aqueous environment [42, 43]. Lipids 
aggregate differently, depending on their physical characteristics, as well as 
on external factors [43]. Biologically typical lipid assemblies include the 
nonlamellar micellar, the lamellar, the hexagonal and the inverted hexagonal 
phases. The lamellar phase describes the bilayer structure, which is the most 
typical lipid aggregate in a biological system.  
 
 
 
Figure 3. Schematic presentation of some lipid aggregates and how the geometry of 
the lipids can affect the aggregate shape. 
 
 
The geometrical shape of the lipid species is the main determinant in the 
formation of these aggregates (figure 3). PC and SM, for example, are 
cylindrically shaped. The cylindrical shape is the result of the similar physical 
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cross-sectional area between the polar headgroup and the acyl chains in the 
lipid. As such, cylindrical lipids form bilayer structures. Geometrically 
conical lipids, that have either large (e.g. lysolipids) or small (e.g. ceramide) 
headgroups, in relation to their acyl chain volume, can form micellar and 
inverted hexagonal structures, respectively [44, 45]. Most membranes in cells 
contain both cylindrical and conical lipids. Lipids with large headgroups, in 
relation to their acyl chain volume, will induce a positive curvature on the 
membrane. Similarly, lipids with smaller headgroups will give rise to a 
negative membrane curvature. In a biological setting, membrane curvature 
arises due to the interplay between the variously shaped lipids, as well as 
certain membrane proteins and membrane-associated proteins [46, 47]. 
Membrane curvature is implicated in a variety of important cellular processes, 
perhaps most notably in the budding, fission and fusion of vesicles [47]. 
 
2.3.1 Bilayer phases 
 
The bilayer lipid structure can be further divided into distinct phases, which 
are classified by the varying spatial arrangement and motional freedom of 
each lipid in the system (figure 4) [48]. Both lipid composition (e.g. length 
and saturation of the acyl chains) and external factors (such as temperature) 
come into play when defining the bilayer phase. In simple lipid systems, 
bilayers generally adopt one of two distinct bilayer phases, depending on 
whether the system exists above or below the main phase transition 
temperature (Tm) of the particular lipid species used. In temperatures below 
the Tm, the bilayer exists in a gel-phase (or “solid-ordered” phase), which is 
characterized by an all trans-configuration of the hydrocarbon chains of the 
lipids. Consequently, the lipids will pack together more tightly, leading to a 
more rigid membrane structure as well as to a decreased lateral diffusion of 
the lipids [43, 48, 49].  
 
When the temperature increases over the Tm, the bilayer adopts a liquid-
crystalline (“liquid-disordered”) phase. This phase is characterized by an 
increasing amount of gauche conformations that are present in the 
hydrocarbon chains. As a result, the lipids pack together more loosely, the 
lipids diffuse more readily, the bilayer expands laterally and the thickness of 
the membrane decreases [43, 48, 49]. When cholesterol is introduced to a 
lipid bilayer system, a third lamellar phase can be formed, i.e. the “liquid-
ordered” phase. In this phase, the lipids are less ordered than in the solid-
ordered phase, but also less fluid when compared to the liquid-disordered 
phase [38]. Here, the acyl chains of the lipids interact with cholesterol to 
adopt an all trans-conformation, similar to that which can be observed in the 
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solid-ordered phase. In model lipid systems, it has been observed that 
cholesterol preferentially interacts with sphingolipids [50, 51]. The umbrella 
model describes this preferential interaction as a cause of the sphingolipids 
shielding cholesterol (using their polar headgroups) from the aqueous 
environment [52].  
 
 
 
 
Figure 4. Schematic representation of the solid-ordered, the liquid-disordered and the 
liquid-ordered bilayer phases. Cholesterol is represented as orange rectangles. 
 
 
2.3.2 Lateral membrane domains  
 
In 1972, the fluid mosaic model (see section 2.1) described the biomembrane 
as a generally homogenous mixture of membrane lipids and proteins. The 
biomembrane contains markedly more lipid species than what is necessary for 
the formation of a simple bilayer. Therefore, a long-standing question has 
been what the purpose of such a complex lipid composition could pertain 
[53]. While the possibility that certain lipids organize as discrete domains in 
membranes had previously been proposed [54–56], it was not until 1997 that 
a more refined hypothesis was put forward, suggesting the existence of 
specific membrane domains (or “lipid rafts”) in the plasma membrane (PM) 
of cells [13]. Lipid rafts (or membrane rafts) are currently defined as “small 
(10 – 200 nm), heterogeneous, highly dynamic, sterol- and sphingolipid-
enriched domains that compartmentalize cellular processes” [14]. Many 
papers have suggested that such lateral domains might play a role in a wide 
range of biological functions, through activation or recruitment of specific 
membrane proteins. GPI-anchored proteins and protein tyrosine kinases are 
examples of enzymes that have been proposed to reside in raft structures [57–
60]. The formation of raft structures has also been implicated in vesicular 
trafficking and in the budding of viruses [61–63].  
 
Generally, research on membrane rafts has focused on the PM, as the outer 
layer of the PM is enriched in both cholesterol and sphingolipids. However, 
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reports of raft-like domains existing in other organelles, such as the 
mitochondria [64, 65], have been presented. Membrane domains have also 
been suggested to exist in endosomes and lysosomes [66], as well as in the 
ER [67, 68]. Additionally, it has been suggested that the sorting of lipids 
destined for PM raft structures already occurs in the trans-Golgi network, 
where sterols and sphingolipids become enriched in secretory vesicles [69]. 
While the literature describes the properties of ordered domains in model 
membrane systems comprehensively [70–75], their existence in natural 
membranes is still lacking in evidence. Initially, the most common methods 
for detecting rafts in biological systems employed non-ionic detergents and 
the extraction of so-called detergent resistant membranes, which are enriched 
in sterols and sphingolipids. These methods, however, are indirect and the 
results they produce are open to alternative interpretation [53]. It is possible 
that the detergent resistant membranes are artefacts created by the extraction 
methods, and therefore would not represent naturally occurring membrane 
domains. Recently, sophisticated microscopy techniques have become 
available, allowing for the observation of clustered membrane domains below 
200 nm in diameter [76–78]. As membrane rafts are also hypothesised to have 
short half-lives (estimated to be in the range of 100 nanoseconds or less [79]), 
their detection is further complicated. The topic of membrane rafts therefore 
remains somewhat controversial, at least until more compelling evidence for 
their natural existence is presented. 
 
2.4 LIPID DISTRIBUTION 
 
In biological systems, lipid distribution is generally not even. The types of 
lipids that are present in different cell types and tissues can vary significantly. 
In addition, lipid variation occurs between the different cellular organelle 
membranes, and even between the two leaflets in the membrane bilayer 
structures. This uneven lipid distribution depends on several factors. First and 
foremost, different lipids are synthesized at different locations in cells. In 
addition, lipids can be transported between membrane structures throughout the 
cell. Since lipids are key players in several essential cellular mechanisms, their 
synthesis and distribution processes have to be tightly regulated for proper 
cellular functioning. 
 
2.4.1 Lipid translocation between the membrane leaflets 
 
The lipid asymmetry within and between the two leaflets in a membrane is 
maintained by a number of processes [4, 37].  Firstly, lipids readily diffuse 
laterally within the membrane plane. Secondly, lipids can translocate between 
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the two leaflets of a bilayer membrane, in a spontaneous fashion. The rate at 
which a spontaneous translocation occurs is dependent mainly on the physical 
properties of the lipid, as well as its surrounding interaction partners. For lipids 
with large headgroups, such translocaion is very slow, whereas lipids with small 
headgroups tend to translocate readily [80–85]. Consequently, cells require 
specific methods for regulating the transbilayer lipid asymmetry, especially in 
the case of large-headgroup lipids. This is achieved with the help of 
translocases (i.e. scramblases, flippases and floppases), which are specialized 
transmembrane enzymes, capable of translocating different lipid species from 
one side of the membrane to the other [6, 7]. Flippases and floppases are ATP-
dependent enzymes that generally localize to the PM. Flippases catalyse the 
translocation of specific lipids from the exoplasmic leaflet to the cytoplasmic 
one, while floppases work in the opposing direction. One of the most studied 
flippase families is the P4-ATPase family of proteins [86]. Atp8a2, a member of 
this family, is responsible for the translocation of PS in photoreceptor disc 
membranes [87]. The floppases include the ATP-binding cassette transporters 
(ABC-transporters). The ABC-transporters are implicated in multiple drug 
resistance, as well as several other cellular processes [88]. MRP1 is an ABC-
transporter that has been suggested to translocate sphingolipids, including 
GlcCer and SM, between membrane leaflets [89]. Scramblases are not ATP-
dependent. The scramblase catalysed translocation of lipids, however, seems to 
be calcium-dependent and non-selective [90]. At least 4 human scramblases are 
expressed in a variety of cells and tissues [91]. 
 
2.4.2 Intracellular distribution and metabolism of lipids 
 
The cell is comprised of several organelles with distinct cellular functions. 
These organelles, like the cell itself, are enclosed by membranes. Lipid 
distribution between the various organelle membranes is not homogeneous. 
For the cells to carry out the multitude of biological processes that occur at 
the various membranes, the correct membrane environments must also be 
present. The intracellular lipid distribution is a result of how and where the 
different lipids are synthesized, as well as how the cell transports lipids from 
their sites of synthesis to their goal destinations. The bulk of the lipid 
trafficking takes place through vesicular transport pathways, which move 
cargo between the various membrane compartments [4, 5]. A brief overview 
of the sites of lipid synthesis, as well as the general lipid distribution between 
the different organelles will be presented here. As ceramide and the GSLs are 
the most relevant lipids in this thesis, their synthesis as well as their cellular 
properties will be discussed more in-depth in sections 2.5 and 2.6.  
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As mentioned in the introduction, lipids are mostly synthesized at the ER [3]. 
The ER produces the bulk of the structural phospholipids and cholesterol, as 
well as ceramide, cholesteryl-esters and triacylglycerol. After synthesis, 
cholesterol is rapidly transported to other compartments in the cell (mainly 
the PM), and as such, the ER generally contains only low amounts of this 
lipid. However, if the cholesterol levels in the PM become elevated, the 
excess cholesterol can be internalized and transported to the ER for 
esterification and subsequent storage in lipid droplets [92]. Ceramide is 
synthesized at (and mainly localized to) the ER [93]. Ceramide is also 
transported to the Golgi apparatus, i.e. the central cellular sorting 
compartment, where it is used as a precursor for more complex sphingolipids. 
A significant level of lipid synthesis takes place at the Golgi, mostly 
regarding the various sphingolipids. Both SM and the GSLs are mainly 
produced here [4].  
 
The PM is enriched in sphingolipids and sterols. The majority of the GSLs, as 
well as SM, localize to the PM. While the PM does not contain enzymes for 
the autonomous synthesis of its main structural lipids, it still serves as a 
platform for several metabolic and catabolic lipid events. SM, for example, 
can be hydrolyzed by a PM-associating sphingomyelinase (SMase), to form 
ceramide and phosphocholine [30]. In addition, it has been suggested that the 
PM contains SM synthesizing enzymes [94]. Similar degradation and 
synthesis events are central in numerous signaling cascades that have been 
detected to occur at the PM [95].  
 
The earlier endocytic membranes are similar to the PM, but the later 
endosomes differ significantly. Most notably, cholesterol and PS decreases 
along the endocytic pathway. The endosomes also contain a system of kinases 
and phosphatases that produce and hydrolyse phosphorylated PIs (i.e. 
phosphoinositides) [95]. The phosphoinositides function as important 
binding-sites for several proteins, allowing for the identification and targeting 
of specific organelle membranes. Significant lipid synthesis occurs in the 
mitochondria. In fact, nearly half of the phospholipids found in mitochondria 
are autonomously synthesized [96]. These phospholipids include phosphatidic 
acid, PG, cardiolipin and PE. Cardiolipin, which is involved in the 
mitochondrial energy metabolism, is exclusively found in this organelle.  
 
The breakdown of lipids (as well as that of most other biomolecules) occurs 
mainly in the lysosomes [97]. Lipids are generally transported to the 
lysosomes via the endocytic and the autophagocytic pathways. The lysosomes 
contain several water-soluble hydrolases, which catalyse the degradation of 
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the biomolecules arriving in the organelle [98]. Consequently, the degraded 
biomolecules can be re-used by the cell. Lysosomes can also fuse with the 
PM and discard their content by exocytosis. Lysosomal dysregulation is 
implicated in several lysosomal storage diseases. The lysosomal storage 
diseases are caused by defects in the genes that produce the various lysosomal 
catabolic enzymes, or their activator proteins, leading to the production of 
inactive or otherwise deregulated variants of said enzymes [99]. As a 
consequence, the targets of the non-functioning enzymes are accumulated in 
the lysosomes, oftentimes leading to severe or fatal complications in the 
patients suffering from the defects. Many sphingolipids are implicated in such 
diseases. The Gaucher, Krabbe and Sandhoff diseases, for example, result in 
the lysosomal accumulation of GlcCer, GalCer and GM2-ganglioside, 
respectively [100]. 
 
2.5 CERAMIDE 
 
Ceramide is a central molecule in the sphingolipid metabolism. Ceramide 
functions as a precursor for all higher sphingolipids and is implicated in a 
variety of cellular processes, including apoptosis, i.e. programmed cell death 
[20]. De novo ceramide synthesis occurs in a stepwise fashion, on the 
cytosolic side of the ER, and is catalysed by several membrane bound 
enzymes (figure 5) [101, 102]. The synthesis begins with the condensation of 
serine and palmitoyl CoA to form 3-dihydrosphinganine, in a reaction that is 
catalysed by serine palmitoyl transferase [103, 104]. 3-deydrosphingasine is 
then rapidly reduced to form sphinganine by the enzyme 3-
dehydrosphinganine reductase [104]. Sphinganine can now be acylated by 
different ceramide synthases to form dihydroceramide, which in turn is 
converted to ceramide by the addition of a trans-4 double bond on the 
sphinganine, by the enzyme dihydroceramide desaturase [105]. Interestingly, 
the sphingoid base sphingosine is not produced de novo, but is only formed 
through the degradation of ceramide [106]. Sphingosine can be further 
modified to produce sphingosine-1-phosphate (S1P), which, in contrast to 
ceramide, is universally involved in survival promotion [107]. At the present, 
five different mammalian ceramidases have been described, one neutral, one 
acidic, and three alkaline [108]. Neutral ceramidase activity has been found 
on the outer leaflet of the PM, whereas the acidic and alkaline ceramidases 
localize to the lysosomes and the ER/Golgi compartments, respectively. Due 
to their differing cellular localization, as well as their varying expression 
patters and substrate specificities, it is likely that each ceramidase is involved 
in distinct cellular activities [108]. 
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Figure 5. Presentation of the pathways of ceramide synthesis. Synthetic and 
degrading enzymes are presented in italics and reaction products are presented in 
bold. The enzymes responsible for ceramide production are color-coded. 
 
 
In addition to de novo synthesis, ceramide can be produced through the 
sphingosine salvage pathway, where sphingosine that has been released by 
ceramide degradation is re-used for ceramide synthesis (figure 5) [109]. 
Ceramide can also be generated by hydrolysis of higher sphingolipids, such as 
ceramide-1-phosphate (C1P), SM and the GSLs. The sphingomyelinase 
(SMase) pathway describes the synthesis of ceramide though the hydrolysis 
of SM by various SMases [29, 30]. A non-lysosomal glucosylceramidase has 
been suggested to produce ceramide through the degradation of GSLs, at or 
close to the cell surface [110]. 
 
2.5.1 The ceramide synthases 
 
The ceramide synthases (CerSs) have emerged as central enzymes in 
sphingolipid metabolism and biology. As previously mentioned, the CerSs are 
responsible for the acylation of sphinganine to produce dihydroceramide, 
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which is subsequently desaturated, yielding ceramide. The CerSs are 
interesting in the sense that they are not only involved in the de novo 
synthesis of ceramide (as described above), but also in the synthesis of 
ceramide directly from sphingosine, through the sphingosine salvage pathway 
[109]. Six distinct CerSs have presently been identified in mammals (CerS1-
CerS6), all of which are believed to primarily reside in the ER membranes, 
where they exhibit their synthesizing activity on the cytosolic side of the 
membrane [111, 112]. The CerSs might, however, also exhibit more specific 
localizations. Indeed, there have been reports that show CerS4 and CerS6 
activity in the mitochondrial membranes [113–115]. Additionally, CerS1 and 
CerS6 show perinuclear staining when overexpressed [116, 117]. One of the 
more notable characteristics of the CerSs, is the ability of the individual 
isoforms to produce ceramides of particular fatty acyl-chain lengths. The 
preference of the different CerSs for producing specific acyl-chain length 
ceramides has been characterized by several studies. All CerSs are acyl CoA 
dependent, and display preference for certain chain length fatty acyl CoA 
molecules (table 1). Data for CerS acyl CoA specificity is generally derived 
from in vitro analysis as well as siRNA and overexpression experiments. 
 
 
Table 1. Summarizing table showing acyl CoA preference and tissues of predominant 
expression of the different CerSs. Information is compiled from various sources (see 
text). 
 
 
CerS1 mainly produces C18 ceramides, and to a smaller extent also C20 
ceramides [118, 119]. CerS2 has a preference for longer-chain fatty acyl 
CoAs (C22-C26) [120–122]. CerS3 demonstrates a relatively broad fatty acyl 
CoA substrate preference, producing ceramides with 18-24 carbon acyl chains 
[123]. Similarly, CerS4 also has a somewhat broader substrate specificity, but 
demonstrated highest preference for producing medium- to long-chain C18 
and C20 ceramides [119, 120]. CerS5 and CerS6 show preference for C14, 
C16, and C18 acyl CoA [120]. The different CerSs also demonstrate varying 
expression patterns in different tissues (summarized in [112]). CerS1, for 
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example is expressed mostly in skeletal muscle and in the brain. CerS2, 
CerS4, CerS5 and CerS6 are more ubiquitously expressed, whereas CerS3 is 
mainly expressed in the testis, prostate and skin. Overall, CerS2 is the most 
widely expressed of the CerSs and is present in most tissues. Additionally, 
CerS expression undergoes changes during development of various tissues 
[124, 125]. Taken together, these findings suggest that the different CerSs 
may be involved in distinct cellular functions, as orchestrated by their 
preferences for producing ceramides of particular chain lengths. 
 
2.5.2 Ceramide in apoptosis 
 
Numerous studies over the past decades have described ceramides as 
bioactive lipids that mediate several different cellular functions, such as cell 
growth, differentiation, and apoptosis [20, 25, 26]. The involvement of 
ceramide in the cellular apoptotic response is quite evident, and ceramide is 
implicated both in the extrinsic and intrinsic apoptotic pathways. Cellular 
ceramide levels are increased in response to a variety of apopototic stimuli. 
These include environmental stresses, chemotherapeutic agents, as well as the 
activation of endogenous apoptotic signaling pathways. Apoptotic inducers, 
such as tumour necrosis factor alpha (TNFα) and Fas ligand (Fas-L) cause 
rapid accumulation of ceramides in many human cell types [126, 127]. 
Additionally, extracellular introduction of short-chain (C2- or C6-) ceramides 
gives rise to apoptotsis [21].  
 
Ceramides function as direct effectors for a variety of enzymes involved in 
the apoptotic signaling pathways, acting to either suppress or increase their 
functions. These enzymes include the kinase suppressor of Ras (a scaffolding 
protein involved in the mammalian mitogen-activated protein kinase [MAPK] 
pathways), Cathepsin D (a lysosomal aspartic protease), the mixed lineage 
kinases (a family of MAPK kinase kinases) and protein phosphatase 2 (a 
serine/threonine phosphatase involved in the regulation of several metabolic 
processes) [128]. Ceramide has been shown to induce apoptosis via the 
mitochondrial pathway, through inhibition of the PI 3-kinase/Akt pathway 
[129, 130]. Additionally, ceramide accumulates in the mitochondria in 
response to apoptotic signals such as toxins, chemotherapeutic drugs and 
TNFα [131]. Accumulation of ceramide at the mitochondrial membrane 
causes permeabilization and consequent release of apoptotic mediators [132]. 
Interestingly, both ceramide derived from the hydrolysis of SM at the PM, as 
well as de novo synthesized ceramide, seem to be implicated in these 
responses [133]. It has also been suggested that the turnover of SM at the PM 
results in the accumulation of ceramide, as well as membrane receptors and 
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other signaling molecules, in sphingolipid-rich membrane domains that may 
act as signaling complexes. These membrane platforms would function to 
potentiate the apoptotic signal transduction, and their formation has been 
suggested to occur in response to a variety of stressful stimuli [131, 134]. One 
of the most studied cases involves the clustering and activation of the 
Fas/CD95 and CD40 cell death receptors in the PM [135–140]. 
 
Precursors, derivatives and degradation products of ceramide are also 
implicated in apoptosis, as well as in cell survival. Sphingosine, like 
ceramide, accumulates in cells that undergo apoptosis [128]. Unlike ceramide, 
however, due to being less hydrophobic, sphingosine is not exclusively 
restricted to membrane fractions. This grants it more flexibility as a second 
messenger. Sphingosine has many identified signaling-related functions in 
cells, of which the best studied example is probably the sphingosine-mediated 
inhibition of protein kinase C [141]. The phosphorylated form of sphingosine 
(S1P) is, as already mentioned, involved in cell survival mechanisms [142]. In 
addition, the glycosylated ceramide derivatives, i.e. the GSLs, are also 
implicated in apoptosis [143]. For example, the ganglioside GD3 has been 
shown to inhibit survival pathways in the mitochondria [144]. 
 
2.5.3 Distinct ceramides with distinct functions 
 
By varying the composition of the hydrophobic tails of the molecule, 
hundreds of distinct ceramides can theoretically be produced. More than 100 
naturally occurring ceramides can be detected using current LC-MS/MS 
technology [145]. With the discovery and characterization of the various 
CerSs and with the help of advanced MS-based analysis methods, the 
ceramides have begun to be defined as a family of distinct lipids with distinct 
functions, instead of being seen functionally as a single entity. Over the past 
decades, evidence for particular ceramide species demonstrating specific 
cellular functions has begun to emerge.  
 
One of the earliest examples of the ceramides structure playing a role in its 
function comes from the observation that ceramide, but not dihydroceramide, 
induces apoptosis and other cellular responses [146]. Later studies have 
revealed that particular chain length ceramides are involved in specific 
cellular activities. For example, when the B-cell receptor is activated in 
lymphocytes, a two-stage accumulation of ceramide occurs [147, 148]. The 
immediate effect shows an increase in C16-ceramide, specifically, whereas in 
the later stages, C24-ceramide levels are elevated. The later stage 
accumulation seems to be dependent of caspase activation, in contrast to the 
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earlier stage. As a whole, this suggests the possibility for distinct ceramides to 
be implicated in different stages of the apoptotic process. Additionally, 
specific ceramides have been implicated in diseases, such as cancer. C18:0-
ceramide levels have been shown to be selectively down-regulated in head 
and neck squamous cell carcinomas [149]. Additionally, overexpression of 
CerS1, which is responsible for the production of C18:0-ceramide, has been 
shown to increase sensitivity of HEK293 cells to several chemotherapeutic 
drugs [150]. In these experiments the increased sensitivity was traced back to 
the selective activation of the p38 MAPK specifically by CerS1, and not by 
the other CerSs. In colon cancer cells, it was found that CerS6 levels were 
very low [117] and that, consequently, the C16-ceramide specific activation 
of the TNF-related apoptosis-inducing ligand (TRAIL) was ineffective. 
Overexpression of CerS6 in these cells lead to the restoration of TRAIL-
induced apoptosis. In contrast, a recent study shows that CerS6-expression is 
up-regulated in non-small-cell lung cancer [151]. CerS6 is also associated 
with cell death induced by interleukin-24 in gliablastoma cells [152] as well 
as with celecoxib-induced cytotoxicity [153]. CerS5 and CerS6 have been 
shown to be involved in the synthesis of long-chain ceramides through the 
salvage pathway, in response to UV-radiation in MCF-7 breast cancer cells 
[154]. In mice, knock out of CerS2 leads to severe liver pathology and 
neurological degeneration [155, 156]. 
 
The many ceramides that exist in eukaryotic cells seem to be involved in a 
multitude of functions, of which apoptosis is particularly evident. While 
differing roles for different ceramides have been suggested, overall, this topic 
remains quite unexplored. The task of elucidating the precise roles of the 
many ceramides is complicated by the number of existing ceramide species 
and by the apparent variability concerning their function in different cells and 
tissues. Additionally, ceramide is a substrate for a multitude of metabolic 
enzymes in cells (estimated >28 distinct enzymes) [20, 157], which adds to 
the complexity of the issue. As such, the characterization of the numerous 
ceramides will be a huge task for future researchers.  
 
2.6 GLYCOSPHINGOLIPIDS 
 
The GSLs, like SM, are derivatives of the ceramides. The GSLs are 
characterized by their carbohydrate moieties, which can vary in both structure 
and number. The compositions of the acyl chains also vary, depending on 
which ceramide species the GSL is based on. The GSLs can be simple or 
complex, ranging from molecules with a single carbohydrate unit, to lipids 
with up to 20 attached sugar residues [31]. In cells, the majority of the GSLs 
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localize to the outer layer of the PM. Similarly to the ceramides, the GSLs are 
believed to take part in a multitude of cellular functions, including cell-cell 
interaction, neurodevelopment and cellular signaling events [158–161]. GSLs 
have also been shown to function as specific receptor molecules for several 
bacterial toxins and hormones [32, 34]. For example, shiga toxin and cholera 
toxin bind to globotriacylceramide (Gb3) and ganglioside GM1, respectively, 
on the PM of cells, prior to their subsequent internalization [162, 163].  
 
2.6.1 GSL synthesis 
 
The simplest GSLs are the glucosylceramides (GlcCer) and the 
galactosylceramides (GalCer). These GSLs consist of a ceramide base, 
coupled to a single glucose or galactose molecule through a β-linkage, 
respectively. GlcCer serves as the basis for most of the higher glycolipids in 
cells. More than 300 GSLs are believed to use GlcCer as a precursor [164, 
165]. The GalCer derivatives are fewer in number, however, GalCer is 
enriched in a variety of tissues. GalCer biosynthesis is associated with 
myelination and as such is strongly coupled to glial cells [33]. Consequently, 
GalCer is enriched in brain tissues, but has also been found to be abundant in 
epithelia of kidney and intestine [166–168]. The site of GalCer synthesis is 
subject to some controversy. Both the ER and the Golgi have been suggested 
as possible sites for the galactosylation process that yields this molecule [169, 
170]. In experiments where two different short-chain ceramide variants were 
used, the galactosylation of 2-hydroxy fatty acid ceramide was shown to 
occur in the ER, whereas non-hydroxy fatty acid ceramide was galactosylated 
in the cis-Golgi [171]. UDP-galactose:ceramide galactosyltransferase 
(GalCerS), the enzyme that is responsible for the transfer of galactose to the 
ceramide backbone, has been shown to reside on the luminal side of the ER 
[172, 173]. GalCer derivatives include the sulfated GalCer variants (the 
sulfatides) and the ganglioside GM4 (figure 6). Like GalCer, sulfatide is 
implicated in neuronal function [174]. The remainder of the GSL-producing 
enzymes are believed to localize to various Golgi compartments [175, 176].  
 
It is generally accepted that GlcCer is synthesized on the cytosolic side of the 
Golgi, by the GlcCer synthesizing enzyme, UDP-glucose:ceramide glucosyl-
transferase (GlcCerS) [177–182]. Ceramide destined to become GlcCer is 
believed to transfer from the ER to the Golgi by vesicular means [183]. The 
majority of the literature describes GlcCer synthesis to be mainly associated 
with the cis/medial-Golgi fractions, however, GlcCerS activity has also been 
observed in the mitochondria-associated membranes (MAMs) which are a 
subdomain of the ER, as well as in the trans-Golgi regions [179, 184, 185].  
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Figure 6. Simplified depiction of the higher sphingolipid synthetic pathways. 
Ceramide and LacCer (boxed) function as branching points in the synthetic pathways. 
 
 
The synthesis of the more complex GSLs takes place by a sequential addition 
of different sugar residues to respective precursor sphingolipids, within the 
lumen of the Golgi. Distinct enzymes transfer the carbohydrate moiety from a 
sugar nucleotide (e.g. UDP-glucose, UDP-galactose and CMP-sialic acid) to a 
specific position on the precursor molecule. Since GlcCer is synthesized on 
the cytosolic side of the Golgi, it must translocate to the luminal leaflet by 
some means, prior to its modification to higher GSLs. Due to its large polar 
headgroup, it is unlikely that GlcCer would flip-flop spontaneously. The 
translocation is therefore believed to be catalysed enzymatically. Indeed, 
fluorescent short-chain GlcCer analogues have been shown to cross the Golgi 
membrane, in a process that is sensitive to ABCB1 multidrug transporter 
inhibitors [184, 186, 187]. However, the aforesaid GlcCer analogues exhibit 
significantly differing membrane properties when compared to their natural 
counterparts, and the data collected may therefore not accurately represent the 
natural processes [188, 189]. Following its translocation to the luminal side of 
the Golgi, GlcCer is galactosylated to form lactosylceramide (LacCer) [190, 
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191]. Once produced, LacCer is not translocated back to the cytosolic side of 
the membrane [192, 193]. Instead, LacCer functions as a branching point in 
the synthesis of the higher GSLs that occurs in the trans-Golgi network. 
These higher GSLs can be characterized by their root structures and comprise 
the globo-, isoglobo-, lacto-, neolacto-, and ganglio-series of GSLs (figure 6) 
[175]. According to the LIPID MAPS Structure Database, some 400 
glycosylated sphingolipids have been identified, varying in both headgroup 
and acyl chain composition [2]. 
 
2.6.2 GSL function 
 
While the GSLs have in some cases been shown to be dispensable when it 
comes to cell survival [194], overall they are essential for normal function in 
multicellular organisms. Removal of specific GSL-synthetic pathways 
oftentimes yields only mild phenotypes. This is generally attributed to the 
compensatory abilities of the remaining GSLs, or alternatively, to the 
specificity of the ablated GSLs in performing very particular functions [195, 
196]. The function of the GSLs has been studied using several different 
approaches. Many GSLs have been shown to be involved in developmental 
processes in mammals. Most of the knowledge pertaining to this comes from 
mouse studies, employing genetic regulation of the various enzymes involved 
in GSL metabolism. Removal of the GlcCer synthesizing enzyme in mice 
leads to embryonic lethality during gastrulation [197]. Similarly, removal of 
the LacCer synthesizing enzyme leads to a termination of embryonic 
development [198]. Based on several studies, elimination of ganglioside 
synthesis seems to have less deleterious effects, however, the various 
gangliosides appear to be involved in the proper development of many 
neuronal functions. Loss of GM3 synthesis has, for example, been associated 
with enhanced insulin sensitivity, impaired neuropsychological behaviour and 
hearing loss [199–201]. Removal of the GA2/GM2/GD2 synthase results in 
male infertility, axonal degeneration, myelination defects, motor deficits and 
Parkinsonism [202–206]. Removal of GalCer synthase similarly induces 
neuronal changes, most probably due to GalCer being a major component of 
the myelin sheaths surrounding the axons [33]. GSLs are also associated with 
several diseases in humans. As mentioned in section 2.4.2, some rare 
lysosomal defects can result in the abnormal accumulation of specific GSLs, 
resulting in severe and oftentimes lethal conditions [99]. Additionally, GSLs 
have been implicated in many cancers. A large number of tumour-specific 
antigens have been identified as GSLs, and changes in GSL expression 
patterns are associated with several different cancer types [161, 207].  
 
Review of the Literature 
 
 29 
As the GSLs are mainly located to the outer layer of the PM, many of their 
proposed functions take place there. As mentioned previously, certain GSLs 
function as binding sites for bacterial toxins, facilitating their entry into the 
cell [32, 34]. Additionally, GSLs at the PM are implicated in cell-cell 
recognition and adhesion, as well as in signaling towards the cell interior 
following these events [158, 159, 161]. A number of GSLs have been found 
to interact with membrane-located proteins and to modulate their function 
[208–212]. The GM3-mediated inhibition of the epidermal growth factor 
receptor at the PM, and the subsequent inhibition of cell growth, is perhaps 
one of the best-characterized examples of such a GSL-protein interaction 
[208]. One unique feature of the GSLs is their ability to self-aggregate and 
cluster in membranes. While the existence of lateral, sphingolipid-enriched 
domains is subject to some controversy (see section 2.3.2), these domains 
have been suggested to serve as platforms for a variety of cellular processes 
[161].  
 
GSLs have also been shown to play roles in the internal organelle membranes 
of cells. For example, a specific function for GlcCer has been shown in the 
Golgi apparatus in melanocytes. While mice with null-alleles for GlcCerS are 
not viable [197], a mutant mouse melanoma cell line that is unable to produce 
GlcCer is proliferative [194]. An interesting observation regarding these cells 
is that despite containing all the enzymes required for pigmentation, they still 
lack the ability to produce melanin [213]. It turns out that GlcCer is required 
for the transport of tyrosinase, the first and rate-limiting enzyme in the 
pigmentation process, from the Golgi to the melansomes. Lack of GlcCer 
leads to tyrosinase accumulation in the Golgi membranes and loss of 
pigmentation. The exact method by which GlcCer facilitates tyrosinase 
translocation is unknown, however, it is postulated that GlcCer is involved in 
the budding of transporter vesicles destined for the melanosomes. 
 
2.7 INTRACELLULAR LIPID TRANSPORT 
 
As mentioned in previous sections, lipids are transported within cells by 
various means. Given their hydrophobic nature, lipid transport generally does 
not occur by their free diffusion through aqueous environments, unless the 
lipid in question is particularly water-soluble. Consequently, the cell utilizes 
alternative methods for the intracellular transportation of lipids (and other 
cargo). These methods will be briefly discussed below. 
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2.7.1 Vesicular transport  
 
Eukaryotic cells are characterized by their endomembranes: a system of 
organelle membranes that are connected to each other by vesicular transport 
along the secretory and endocytic pathways. Vesicular transport is the major 
method by which cells traffic cargo in and out of the cell, as well as between 
various membrane-bound compartments within the cell. The bulk transfer of 
lipids also occurs by this method [4, 5]. Cellular vesicles are bilayer 
constructs consisting of lipids and proteins and are produced in tightly 
regulated budding processes at the membranes of the various organelles. 
Vesicles are constantly budding from and fusing with organelle membranes, 
especially at the PM, the ER and the various Golgi cisternae. The budding 
process is initiated by the accumulation of certain lipids and proteins at the 
membrane surface. As mentioned in section 2.3, the clustering of conically 
shaped lipids (and shaped transmembrane proteins and membrane-associated 
proteins) impart membrane curvature and helps initiate vesicle budding [47].  
 
The cytoplasmic surface of the forming vesicle is coated with specialized 
coating proteins, which are recruited from the cytosol [214]. The coating 
proteins are the main driving force behind the distortion of the membrane, 
and act to stabilize the shape of the curving membrane. The coat proteins, 
together with transmembrane cargo receptors, are also used to recruit specific 
cargo to the site of vesicle formation. The formation process is completed by 
the budding membrane being “pinched off” by enzymatic means, which leads 
to the cargo being engulfed within the vesicle. Over short distances, vesicles 
travel by diffusion. Transport over longer distances, such as when vesicles 
move from the Golgi to the PM, is facilitated by motor proteins that move the 
vesicles along the cytoskeletal filament. As the vesicle fuses with its target, 
the cargo within the vesicle is released into the opposing side of the 
membrane, and the lipid and protein constituents of the vesicle bilayer are 
combined with the target membrane. Prior to fusion, the protein coat 
surrounding the vesicle is disassembled. 
 
Several types of coated vesicles exist. The first to be characterized were the 
clathrin coated vesicles, which function to internalize extracellular material at 
the PM, as well as to transfer cargo from the trans-Golgi to the lysosomes 
(figure 7) [215]. In addition, clathrin-independent internalization has been 
shown to occur [216]. For example, caveolar endocytosis involves the 
caveolin coat and is utilized in the internalization of GSLs and some viruses. 
The COP (coating protein) -coated vesicles are responsible for the trafficking 
of vesicles between the ER and the various Golgi cisternae (figure 7). COPII-
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coated vesicles bud at the ER and carry their cargo towards the Golgi 
complex, where the cargo is sorted and modified according to cellular needs. 
In contrast, COPI-coated vesicles traverse in the opposite direction, in 
retrograde transfer from the Golgi to the ER, as well as from later to earlier 
Golgi cisternae [217]. The method by which cargo is transported through the 
Golgi cisternae is not fully understood, but several models have been 
proposed [218]. All eukaryotic cells have constitutive secretory vesicles, 
which continuously bud from the trans-Golgi network and travel to the PM. 
This process delivers lipids and proteins to the cell surface, and allows for the 
release of cargo to the outside of the cell by the process of secretion [219]. 
Cells with dedicated secretory functions (such as endocrine cells) can store 
secretory vesicles in the cytoplasm, until the cell receives an appropriate 
signal and the vesicles fuse with the PM and release their content into the 
extracellular environment. 
 
 
 
 
Figure 7. Simplified presentation of known vesicular transport routes along the 
endomembrane system in a cell. The COPI-, COPII- and clathrin-coated vesicles, as 
well as the secretory vesicles, are depicted. The blue arrows indicate cargo moving 
along the various Golgi stacks. 
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Proper cellular function requires for transport vesicles to be selecively 
targeted to their goal destination. This recognition and initial attachment (i.e. 
tethering) is believed to occur through the interplay of so-called tethering 
factors on the target membranes, and specific targeting GTPases (Rabs) on 
the vesicles surface [220]. The subsequent fusion of the vesicle to the target 
membrane is believed to be facilitated through the pairing of SNARE proteins 
(soluble N-ethylmaleimide-sensitive factor attachment protein receptor), 
where a SNARE on the transport vesicle (v-SNARE) pairs with its 
complementary target membrane SNARE (t-SNARE) [221]. 
 
2.7.2 Lipid transfer proteins 
 
In addition to the vesicular transport mechanisms, LTP-mediated lipid 
transfer has emerged as an important method of lipid translocation in cells [8, 
9, 222]. While many proteins have the capacity to interact with lipids, the 
LTPs are specifically defined as proteins that facilitate and/or accelerate a 
lipid exchange between membranes in vitro [9]. Additionally, LTPs are 
characterized by the presence of a lipid-binding hydrophobic pocket in their 
structures and they generally show specificity for a particular lipid species. 
Several LTPs have been discovered in eukaryotes, plants and in bacteria. 
Many of these LTPs have been cloned and crystallized, allowing for their 3D-
structures to be determined. LTPs can be divided into several protein families, 
based on the sequence and structure similarity of their lipid binding domains. 
In eukaryotes, these families include the SEC14 family, the SCP-2 family 
(sterol carrier protein 2), the plant nonspecific lipid transfer proteins (plant 
nsLTPs), the PITPs (phosphatidylinositol transfer proteins), the STARTs 
(steroidogenic acute regulatory protein-related lipid transfer proteins), the 
GLTPs (glycolipid transfer proteins) and the ORPs (oxysterol-binding 
protein-related proteins), and are summarized in table 2 [223–228]. The 
different LTP families will be discussed below briefly. 
 
The PITPs are a family of proteins that transfer PCs and PIs between 
membranes in vitro [229]. In mammals, the PITPs consist of at least five 
members: PITPα, PIPTβ, RdgBβ, Nir2 and Nir3. The first two are referred to 
as Class I PITPs, whereas the last three are Class II PITPs [9]. PITPs are 
implicated in phosphoinositide metabolism and related cellular processes, 
such as phospholipase C signaling and exocytosis [230, 231]. The members 
of the SEC14 family also transfer PCs and PIs, however, SEC14s do not share 
sequence or structure homology with PITPs [232]. The prototype SEC14 
family member is the yeast protein Sec14p, which is strongly implicated in PI 
and PC metabolism in yeast cells [223].  
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The STARTs are a protein family characterized by their START domains. 
Various START family members bind and transfer different lipid species, 
such as cholesterol, ceramide and PC [233]. The archetypical START domain 
is found in the steroidogenic acute regulatory protein (StAR), which mediates 
cholesterol transfer in the mitochondria [234].  
 
 
Table 2. Summarizing table of the different LTP families. 
 
 
The mammalian sterol carrier protein 2 (SCP-2) transfers cholesterol, most 
phospholipids, glycolipids, fatty acids and fatty acyl CoA and is considered a 
nsLTP [235–237]. The gene for mammalian SCP-2 encodes two proteins: the 
aforementioned SCP-2, as well as a protein called SCPx [228]. SCPx has 
been shown to play a crucial role in the peroxisomal oxidation of branched-
chain fatty acids [238]. SCP-2 is implicated in cholesterol biosynthesis, 
uptake, oxidation, esterification and recycling [239–241].  
 
SCP-2 should not, however, be confused with the plant nsLTPs, which are 
structurally distinct from SCP-2 and are considered as a separate family of 
proteins [242]. Plant nsLTPs are involved in a variety of functions, including 
stabilization of membranes, cell wall organization, and signal transduction 
[242]. The plant nsLTPs can bind a variety of lipids, including fatty acids, 
phospholipids, glycolipids and prostaglandin B2 [243]. 
 
The ORPs are present in a wide range of eukaryotes. In mammals, these 
proteins are encoded by 12 genes, yielding several more ORP products due to 
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splice variation and different promotors [228]. The ORPs contain a beta-
barrel-like ligand-binding domain that is able to bind sterols, and in some 
cases, phospholipids [244]. While ORPs have been implicated in cellular 
sterol transport, conclusive evidence for this function has not emerged [227]. 
ORPs have been shown to be involved in sensory and signaling events in 
cells. For example, the oxysterol-binding protein (OSBP, the founder of the 
ORP family), acts as a sterol-sensing scaffolding factor and regulates the 
dephosphorylation of the extracellular signal activated kinases [245].  
 
The lipid specificities and transferring capabilities of the various LTPs have 
generally been determined by in vitro lipid-transfer assays, using either radio- 
or fluorescently labeled lipids [9, 10]. While the LTPs are named based on 
their proficiency for transferring specific lipids in vitro, it is not always clear 
whether or not their in vitro transfer capabilities reflect their physiological 
functions. This is a recurring problem within the field of LTP-research, which 
stems from the lack of methods for direct observation of in vivo LTP-
mediated lipid transfer. As mentioned above, alternative roles for various 
LTPs have been proposed, such as signaling, sensory or reporter functions [8, 
9]. For example, Nir2 has been suggested to sense and regulate the levels of 
PC in the Golgi membranes [246].  Nevertheless, some LTPs are believed to 
be de facto lipid transporters. For example, the ceramide transfer protein 
(CERT) is a START family protein which has been shown to catalyse the 
transfer of ceramide from the ER to the site of SM synthesis at the late Golgi 
[247, 248]. Another de facto LTP is the four-phosphate adaptor protein 2 
(FAPP2), a GLTP-family protein which is required for the transfer of GlcCer 
to the late Golgi compartment and for the subsequent modification of GlcCer 
to higher GSLs [183, 249]. The remaining sections of this literature overview 
will focus on the GLTP family of LTPs, and its founding member, the 
mammalian GLTP. 
 
2.7.3 The glycolipid transfer protein  
 
GLTP was first described by Metz and Radin in the early 1980s, who 
demonstrated that a protein residing in the cytosolic fraction of bovine spleen 
was able to transfer GlcCer between rat erythrocytes and liposomes in vitro 
[250]. Since its initial discovery, GLTP and several of its homologs have been 
found in a wide range of tissues and organisms, including mammals, plants 
and yeast [183, 251–254]. The human gltp gene is located on chromosome 12 
at locus 12q24.11. An additional, transcriptionally silent pseudogene for 
GLTP has been found on chromosome 11 [255]. GLTP is a small (~24 kDa, 
209 amino acids) soluble protein, which resides in the cytosol [256] and has 
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been shown to bind and transfer a wide range of GSLs between model 
membranes [10]. Over the years, several of GLTP's biochemical 
characteristics have been determined. These include, among others, the 
structural determinants that allow for GLTP to interact with membranes and 
bind lipids. Despite being biochemically well characterized, the cellular role 
of GLTP remains elusive. The fact that GLTP is widely expressed and highly 
conserved between many different organisms suggests that it plays an 
important biological function. 
 
 
Figure 8. Surface (van der Waals) rendering (left) and a cartoon representation (right) 
of a crystal structure of human GLTP, complexed with GlcCer containing an 18:1 
acyl chain (stick cartoon). The up- and the down-stream FFAT-like motifs are seen as 
yellow and orange, respectively. W96 and W142 are represented in red and magneta, 
respectively. The image was created in PyMol using a pdb-file (3S0K) obtained from 
the RCSB protein data bank.  
 
 
Initial studies on GLTP function were hampered by labor-intensive 
purification processes, which resulted in low yields of purified GLTP [257]. 
In the early 2000s, the successful molecular cloning of the gltp gene allowed 
for rapid production of various mammalian GLTPs, and ushered in a new era 
of GLTP-research [251, 258]. Large quantities of pure GLTP allowed for the 
crystallization of the protein and the subsequent determination of the GLTP 
3D-structure [259–261]. To date, several crystal structures of GLTP are 
available in the Protein Data Bank, both in the ligand-free apo-form as well as 
complexed with various GSLs. The GLTP-fold is unique from many other 
LTPs in that it consists of an all alpha-helical structure, arranged as two 
orthogonal layers that “sandwich” a single glycolipid (figure 8). The unique 
structure and the specificity for glycolipids eventually lead to GLTP 
becoming the founding member of a new superfamily of proteins [262, 263].  
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Molecular mapping studies on the glycolipid-binding site of GLTP show 
thatthree distinct regions on the GSLs are involved in the formation of the 
GLTP-GSL complex: the sugar headgroup, the amide-linkage on the 
ceramide backbone and the hydrophobic acyl chains [260–262]. The 
involvement of these regions is evidenced by studies showing that GLTP-
mediated GSL transfer is unaffected by free sugars, and that GLTP exhibits 
poor interaction with mono-chain glycolipids [264, 265]. In mammalian 
GLTPs, the anchoring of the glycolipid sugar headgroup is stabilized by 
several hydrogen-bonds, involving the amino acid residues aspartic acid 48, 
asparagine 52, lysine 55 and tyrosine 207, whereas histidine 140 and aspartic 
acid 48 are involved in the recognition and binding of the amide on the 
ceramide backbone [226, 261]. Tryptophan 96 (W96) is key in helping to 
orient the hydroxyl group on the first sugar moiety of the glycolipid substrate 
for proper hydrogen bonding. Consequently, W96 has been shown to be 
essential for the glycolipid transfer activity of GLTP [261, 265, 266]. A point-
mutant of GLTP, that replaces W96 with alanine (W96A), exhibits an almost 
complete lack of transfer activity. 
 
The membrane interaction region of GLTP is composed of several non-polar 
amino acid residues that form a ring around the opening to the hydrophobic 
cavity [226]. These residues are typical for membrane interaction, but are 
organized spatially in a way that differs from certain other membrane-lipid 
binding motifs, such as the C1 and C2 domains found in phospholipases and 
protein kinases, as well the pleckstrin homology, FYVE and phox domains 
that bind to the PIs [267–269]. These particular lipid-binding domains bind to 
the lipid headgroup while the lipid remains bound to the membrane, whereas 
GLTP embeds the lipid hydrophobic chains inside its structure, following its 
binding to the membrane and recognition of the sugar group on the 
glycolipid. Variation in the residues surrounding the sphingolipid binding site 
occur between several GLTP homologs [263, 270, 271]. Consequently, 
electrostatic differences at these sites may be one determinant for the GLTP-
membrane interaction, where differently charged lipids may act to regulate 
the GLTP binding. Tryptophan 142 (W142) has been shown to be essential in 
the binding of GLTP to the membrane [261, 265, 266, 272–275]. W142 is 
involved in the initial docking process to the membrane and most likely 
functions as an interfacial tether that allows for the proper orientation of 
GLTP in respect to the membrane plane. A third tryptophan residue, W85, is 
proposed to maintain the proper structural folding of GLTP [273].  
 
The cavity that houses the acyl chains of the bound glycolipid substrate is 
adaptable and can envelop GSLs of different chain lengths. Analysis of the 
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crystal structures of GLTPs in either apo- or ligand-bound forms has revealed 
that the binding of a glycolipid exhibits a structural shift in the alpha-2 and 
alpha-6 helices, which may relate to the process by which GLTP dissociates 
from the membrane, following glycolipid detection and uptake [271]. The 
various chain length GSLs that have been co-crystallized with GLTP exhibit 
either a “sphingosine-in” conformation, where both acyl chains are embedded 
within the protein, or a “sphingosine-out” conformation, where the amide-
linked chain occupies most of the cavity, subsequently preventing the 
sphingosine from entering [262]. The sphingosine-out conformation is 
observable in GLTP structures co-crystallized with longer-chain GSLs, such 
as 24:1-GalCer. Whether or not these conformations are also present in 
biological systems remains to be determined, however, a sphingosine-out 
conformation logically might allow for increased membrane interaction. 
 
The glycolipid specificity, the membrane binding characteristics and the lipid 
transfer activity of GLTP have been established through various studies, 
employing several different methods. For example, the utilization of lipid 
monolayers [276], radiolabel transfer assays [277], fluorescence resonance 
energy transfer (FRET) assays [278] and recently, surface plasmon resonance 
(SPR) [275], have resulted in a thorough biochemical characterization of the 
factors that affect GLTP functionality. Various parameters regarding the 
membrane that surrounds the glycolipid substrate have been shown to 
influence the GLTP-mediated transfer, such as membrane lipid composition, 
curvature and packing. Glycolipid transfer from negatively charged vesicles is 
significantly slower than from neutral or positively charged vesicles [279]. As 
GLTP is positively charged at neutral pH (pI =9.0), it is plausible that a 
negatively charged vesicle yields a stronger electrostatic interaction between 
the protein and the membrane, consequently slowing down GLTP 
dissociation. GLTP is unable to transfer glycolipids from vesicles made of 
saturated SMs [280], however, SM analogues that resemble PC allow for 
transfer to occur. The 3-hydroxy group and the trans-4,5 double bond on the 
sphingosine in SM are determinants for the reduced GLTP-mediated transfer 
[278]. Membranes consisting of saturated SM allow for transfer, however, at 
a significantly reduced rate when compared to membranes of chain-matched 
PC [280, 281]. 
 
Membrane curvature seems to significantly affect GLTPs ability to extract 
glycolipids. Transfer rates are several-fold higher from small, highly curved 
POPC (1-palmitoyl-2-oleyl-sn-glycero-3-phosphocholine) vesicles, when 
compared to more planar bilayers [282]. Similarly, GLTP does not extract 
glycolipids from POPC monolayers with biomembrane-like packing [276]. 
Review of the Literature 
 
 38 
This is perhaps not unexpected, as curved membranes exhibit less membrane 
packing, allowing for easier glycolipid extraction. Recently, it was shown that 
GLTP is able to extract glycolipids from high surface-stress planar 
monolayers that were composed of POPC and physiological amounts of PE or 
PA [283]. These results somewhat contradict previous studies where 
negatively charged lipids in POPC vesicles act to inhibit GLTP transfer [279, 
282]. However, monolayer systems also allow for lipids to move more freely 
out of the membrane plane, as there are less hydrophobic forces to keep the 
lipids in place [271]. Interactions between the glycolipid headgroup and the 
surrounding membrane presumably also determines the observed effect of 
adding PE or PA to the membrane, where the smaller PE and PA headgroups 
allow for increased glycolipid uptake, as the larger headgroup of the PC will 
act to shield the glycolipids in an “umbrella-like” fashion. Taken together, 
these results suggest that the biological membrane lipid composition, as well 
as the curvature of the membrane, may act to regulate GLTP function in cells. 
Speculatively, GLTP may exhibit a bifunctional role, where it functions as a 
transporter of lipids at highly curved membrane contact sites (MCSs), and as 
a sensor at more planar membranes surfaces. 
 
Interestingly, glycolipids are not required to be present in the membranes for 
GLTP/membrane interaction to occur [275, 282]. It is also not necessary for 
glycolipids to be embedded in membranes for GLTP/glycolipid-
complexation, as it has been observed that GLTP can bind substrates that are 
dispersed in aqueous solutions, either as monomers or micellar structures 
[284]. GLTP transfers a variety of glycolipids between model membranes, 
including GlcCer, GalCer, LacCer and sulfatide, as well as various 
gangliosides and globosides (reviewed in [10]). SM, cholesterol, PI, PE and 
PC are not transferred by GLTP in similar systems [277]. A characteristic 
feature in the glycolipids, that enables their transfer by GLTP, is the β-linkage 
between the sugar group and the lipid moiety [285]. Early studies suggested 
that GLTP was able to transfer both sphingoid- and glycerol-based 
glycolipids, however, the accuracy of these claims has recently been brought 
into question [10]. Based on the transfer kinetics from the various studies, it 
would seem that GLTP prefers simpler glycolipids, such as GlcCer, GalCer 
and LacCer, as its substrates. Ganglioside GM1 seems to be an exception to 
this rule, and exhibits similar transfer rates to those of the simpler GSLs [10]. 
 
2.7.4 Possible in vivo functions of GLTP 
 
In the literature, most studies regarding GLTP have focused on its 
biochemical characteristics, such as its structure, membrane binding 
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determinants and substrate specificity. The biological role of GLTP is still 
unclear. GLTP has been shown to be a cytosolic protein [256], which is an 
important determinant for deciphering its biological function. This is evident 
when considering that GlcCer is the only GSL that is synthesized on the 
cytosolic surface of a membrane (see section 2.6.1), making it a prime 
candidate for GLTP interaction. Additionally, by comparing GLTP to other, 
biologically more characterized LTPs, one is able to extract subtle hints 
towards its in vivo function.  
 
Several GLTP homologs have been identified, many of which have been 
implicated in particular cellular functions. The fungal heterokaryon 
incompatibility protein HET-C2 exhibits high sequence identity to 
mammalian GLTP [253]. X-ray crystallography analysis of HET-C2 reveals a 
structure that is highly similar to the mammalian GLTP-fold. HET-C2 has 
been shown to transfer monohexocslceramides in vitro, however at a slower 
rate than mammalian GLTP [286]. Nevertheless, when comparing to 
mammalian GLTP, the key amino acid residues in the carbohydrate 
interacting site are almost completely conserved [253]. In general, genes at 
the HET loci are known to regulate cell-cell interaction events in fungi [287]. 
As such, a similar function for GLTP might be evident in mammalian cells. In 
Arabidopsis thaliana, two GLTP homologs have been found, namely 
AtGLTP1 and the accelerated cell death 11 protein (ACD11) [252, 254]. 
AtGLTP1 is able to transfer GlcCer between model membranes, whereas its 
ability to translocate GalCer and LacCer is comparatively diminished [252]. 
AtGLTP1 has been suggested to direct GSLs to the PM, and to possibly 
control the formation of GSL membrane domains. ACD11 has been shown to 
accelerate the inter-membrane transport of sphingosine, but not that of GSLs 
[254]. ACD11 is strongly implicated in apoptosis: when ACD11 is down-
regulated, a programmed cell death response is activated [254]. Interestingly, 
expression of human GLTP in plants with diminished levels of ACD11 leads 
to a delay in the apoptotic response [288], suggesting a possible role for 
GLTP in the mammalian apoptotic pathways. Recently, a mammalian GLTP 
homolog was identified to bind and transfer the phosphorylated ceramide 
metabolite, C1P [270]. This transfer protein, previously known as human 
GLTPD1, was named as the ceramide-1-phosphate transfer protein (CPTP). 
CPTP has structurally a similar fold to that of GLTP, however, CPTP does 
not transfer GSLs. As such, CPTP seems to hold more in common with the 
plant ACD11, rather than with mammalian GLTP. 
 
The mammalian four-phosphate adaptor protein 2 (FAPP2) is a protein that 
contains a GLTP homology domain in its C-terminus. Like GLTP, FAPP2 
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transfers GlcCer between membranes in vitro [183]. FAPP2 has been shown 
to play an important role in glycolipid events occurring at the trans-Golgi 
network. More specifically, FAPP2 is required for the synthesis of 
globotriacylceramide (Gb3) [249]. FAPP2 is believed to bind and transfer 
GlcCer from the cytosolic side of the early Golgi to the later Golgi 
compartments, where GlcCer is subsequently converted to LacCer on the 
luminal side of the organelle. Down-regulation of FAPP2 synthesis results in 
a dramatic decrease in the overall globoside production, whereas ganglioside 
synthesis remains uninterrupted [249]. As such, FAPP2 plays a key function 
in the branching pathways of the higher GSLs. Additionally, these findings 
suggest that at least two different LacCer pools exist in the later Golgi 
compartments, each of which is destined to function as a precursor pool for a 
particular type of higher GSL. FAPP2 is also implicated in cellular protein 
trafficking events, and has been shown to tubulate membranes in vitro [289–
292].  
 
In contrast to GLTP, which is a single-domain protein, FAPP2 contains 
additional structural domains. These include the 120 amino acid pleckstrin 
homology (PH) domain, which is a common structure in many LTPs and 
other lipid-binding proteins [268, 293]. In FAPP2, the PH-domain specifically 
recognizes PI4P and the GTPase ADP-ribosylation factor (ARF) on the trans-
Golgi network [183, 290]. Additionally, PH-domains have been shown to 
bind to the βγ-subunits of heterotrimeric G proteins, as well as to protein 
kinase C [294, 295]. Other LTPs that contain a PH-domain include CERT and 
many of the ORPs. These proteins are likewise implicated in functions 
involving the Golgi membranes. CERT is responsible for the transfer of 
ceramide from its site of synthesis at the ER to the Golgi, where ceramide is 
further modified to produce SM [296]. The founding member of the ORP 
family, OSBP, is implicated in sterol synthesis as well as in various aspects of 
sterol regulation [227, 244]. Like FAPP2, both CERT and OSBP are believed 
to localize to the Golgi through their PH-domains [297, 298].  
 
While GLTP does not contain a PH-domain, it contains a motif that is 
common to many LTPs. FFAT-motifs (two phenylalanines in an acidic tract) 
with consensus sequences (EFFDAxE) are known to allow for interaction 
with the ER-residing VAPs (vesicle-associated membrane protein-associated 
proteins) [299–301]. Other examples of FFAT-containing LTPs include 
CERT, FAPP2, OSBP and ORP3 [300, 302–304]. Based on experimental 
results, variations in some of the amino acids in the consensus FFAT-
sequence can be tolerated, regarding VAP interaction [299]. Indeed, GLTP 
contains two “weak” FFAT-like motifs (figure 8 and 9) and has been shown 
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to bind to VAP-A both in vitro and in vivo [305] (unpublished results), which 
would suggest an ER-specific function for GLTP. Of the two motifs, in 
humans, the upstream one (amino acids 22-28) is weaker than the 
downstream one (amino acids 32-38), in respect to predicted VAP-binding 
capacity [304]. It has been suggested that both FFAT-like motifs may be 
synergistically involved in VAP-binding [304], however, mutation of the 
downstream motif is enough to inhibit GLTP-VAP-A interaction [305]. In 
FAPP2, two “weak” FFAT-like motifs are localized similarly to the FFAT-
like motifs in GLTP (figure 9). Additionally, a third FFAT-like motif exists 
in mammalian FAPP2 [304]. When the most optimal FFAT-like motif in 
FAPP2 was tested for ER-interaction in a yeast model system, no targeting 
could be observed. Phosphorylation of the serine in this FFAT-like motif, 
however, resulted in weak interaction with VAP-A. Similar phosphorylation 
of a serine near the FFAT-motif in CERT has been shown to affect its binding 
to VAP-A [306], suggesting that post-translational modification may be a 
common method of regulating LTP-VAP interaction. 
 
 
Figure 9. Schematic representation of the human GLTP and FAPP2 secondary 
structure. The zoom in represents the amino acid sequence from the N-terminal side 
of the GLTP-domain in each protein. The FFAT-like motifs are shown as red, 
together with the consensus FFAT motif (boxed). PH = pleckstrin homology domain, 
GLTP = GLTP domain. 
 
 
Since GlcCer is the most probable biological substrate for GLTP, it is 
plausible that GLTP localizes to the cytosolic side of the Golgi compartment, 
i.e. the site of GlcCer synthesis (figure 10). Additionally, it is possible that 
GLTP interacts with GlcCer that localizes to the ER. In one study, the 
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FAPP2-dependent synthesis of higher GSLs was suggested to occur through a 
retroactive transport of GlcCer from the Golgi to the ER [184]. In this model, 
once GlcCer arrives at the ER, it would be flipped to the luminal side and 
subsequently be transported back to the Golgi by vesicular means. These 
findings are supported by a more recent study, where ER-resident flippases 
were shown to translocate GlcCer between the bilayers of isolated ER 
membranes [307]. Hypothetically, GLTP might sense GlcCer at the ER and 
regulate its sorting into vesicles, through its interaction with VAP-A. Indeed, 
VAP-A has been shown to interact with various SNAREs and, as its name 
implies, is involved in vesiculation events [308, 309]. 
 
Both GLTP and FAPP2 have been implicated in the non-vesicular transport 
of GSLs to the PM, however, the process by which this occurs is not clear 
[184]. The non-vesicular transport of GlcCer to the PM was first observed by 
Warnock et al. some 20 years ago [310]. Despite brefeldin A (BFA) 
treatment, which results in inhibiton of the secretory transport pathway from 
the ER to the PM, GlcCer still arrived at the PM in Chinese hamster ovary 
cells. The non-vesicular trafficking of GlcCer was suggested to be protein-
mediated. Later, it was demonstrated that down-regulation of either GLTP or 
FAPP2 resulted in a decreased transfer of GlcCer to the PM [184]. Neither 
GLTP- nor FAPP2-down-regulation in BFA-treated cells resulted in a 
complete inhibition of GlcCer transport to the PM, suggesting that GLTP and 
FAPP2 may compensate for each other regarding this function. Alternatively, 
the transport might be taken over by a third, unidentified LTP. Interestingly, a 
simultaneous knockout of GLTP and FAPP2 did not yield viable cells, 
suggesting that together, these proteins are essential for cell survival.  
 
The actions of many LTPs may be linked together. Indeed, OSBP has been 
shown to regulate CERT activity in cells [311]. OSBP is necessary for the 
formation of a VAP-CERT complex, however, by itself OSBP does not seem 
to interact strongly with CERT. Consequently, it is not too far fetched to 
speculate that there may be a wider synergistic function between the various 
FFAT-motif containing LTPs, where they act together to maintain the lipid 
homeostasis in cells. FAPP2 and GLTP may very well regulate each other's 
functions, similarly to that of CERT and OSBP. GLTP and FAPP2 do not 
seem to exhibit any level of interaction in vitro, as assayed by FRET-assays 
and pull-down experiments (unpublished results). This does not, however, 
exclude the possibility that GLTP and FAPP2 may interact indirectly, or 
through mediators, in cells. Other factors, such as post-translational 
modifications, may also come into play when considering these possible 
protein-protein interactions.  
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Figure 10. Simplified schematic of established and hypothesized cellular 
localizations and functions of some sphingolipid transferring proteins. FAPP2 
catalyses the transfer of GlcCer from its site of synthesis in the early Golgi to later 
Golgi compartments for subsequent LacCer and Gb3 synthesis. This occurs either 
directly, or possibly by a retrograde pathway through the ER. CERT transports 
ceramide from the ER to the trans-Golgi, presumably at ER-Golgi contact sites. 
FAPP2 and CERT associate with PI4P on the Golgi membrane through their PI 
homology domain. Both GLTP and FAPP2 have been implicated in the transfer of 
GSLs to the PM. GLTP may bind GlcCer at the Golgi or possibly at the ER. CERT 
interacts with VAPs at the ER. Both GLTP and FAPP2 might also exhibit VAP 
interaction.
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3. AIMS OF THE STUDY 
 
The general aims of the work done for this thesis were twofold. Firstly, the 
role of GLTP was to be examined in relation to GSL metabolism in cells. 
Secondly, a new ceramide delivery system for cells in culture was to be 
studied and developed. More specific aims of each of the publications are 
listed below. 
 
The main aim of publication I was to alter the cellular GSL content, and to 
subsequently study what effects these alterations have on the cell, in respect 
to GLTP expression and protein levels. Inhibitors of vesicular transport and 
sphingolipid synthesis, as well as RNA interference, were utilized for this 
purpose. In publication II, the aim was to analyse the lipidome of cells with 
altered GLTP expression. Cellular GLTP levels were genetically up- or 
down-regulated and the changes in the cellular lipidome were examined. 
 
The aim of publication III was to study and develop a solvent-free method 
for introducing various chain length ceramides to cultured cells. The 
ceramides were complexed with cholesteryl phosphocholine to form stable 
bilayer vesicles, and were subsequently introduced to cultured cells by 
addition to the growth medium. The ceramide uptake, the effects that the 
ceramides had on cell proliferation, as well as the cellular fate of the 
introduced ceramides, were analysed.  
 
In addition, unpublished results are discussed and presented in this thesis, 
regarding data that supports the various observations made in the published 
works.
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4. EXPERIMENTAL PROCEDURES 
 
A brief summary of the experimental procedures is presented here. A more 
comprehensive overview of the different methods used in this thesis can be 
found in each of the original publications. 
 
4.1 Materials and chemicals (I, II and III) 
 
All chemical reagents were of analytical grade or higher. Lipid standards 
where from Avanti Polar Lipids (Alabaster, USA) or Matreya LLC (Pleasant 
Gap, USA). Cholesteryl phosphocholine was synthesized as described by 
Lönnfors et al. [312], or obtained from Avanti Polar Lipids. D-erythro-
sphingosine and hexanoic acid were purchased from Larodan (Malmö, 
Sweden). [3-3H]D-erythro-sphingosine and [9-10,3H]hexadecanoic acid were 
obtained from PerkinElmer (Waltham, MA, USA). Decanoic and 
hexadecanoic acids were obtained from Sigma-Aldrich (St. Louis, MO, 
USA). Acetic acid and organic solvents were from Rathburn Chemicals Ltd 
(Walkerburn, Scotland) or Avantor Performance Materials (Center Valley, 
PA USA). Monensin, brefeldin A and N-butyldeoxynojirimycin were 
obtained from Toronto Research Chemicals (North York, ON, Canada). 
Myriocin, 1-phenyl–2-decanoylamino-3-morpholino-1-propanol and protease 
inhibitor cocktail were purchased from Sigma (St. Louis, MO, USA). [4, 5-
3H]-sphinganine was a kind gift from Dr. Tony Futerman (Weizmann Institute 
of Science, Israel). Conduritol-B-epoxide was purchased from Merck 
Chemicals (Calbiochem) (Darmstadt, Germany) and tunicamycin was 
purchased from Enzo Life Sciences (Farmingdale, NY, USA). Chloroquine 
and ceranib-2 were purchased from Sigma-Aldrich and fumonisin B1 was 
purchased from Enzo Life Sciences (Farmingdale, NY, USA). The polyclonal 
rabbit antibody against GLTP has previously been described [256]. The rabbit 
anti-beta actin antibody was from Rockland Immunochemicals (Gilbertsville, 
PA, USA). The rabbit anti-GlcCer and anti-GalCer antibodies were from 
Glycobiotech, GmbH (Germany). The secondary peroxidase-conjugated anti-
rabbit antibody was from Thermo Scientific (Waltham, MA, USA). The 
expression plasmid encoding human GLTP has been described previously 
[256]. The empty green fluorescent protein vector (pEGFPN1) was from 
Clontech (Palo Alto, CA, USA). The various siRNAs, the universal negative 
control siRNA and the fluorescein isothiocyanate labeled (FITC) dsRNA 
oligomers were from Invitrogen (Carlsbad, CA, USA). The primer pairs used 
for qPCR analysis were obtained from DNA Technology A/S (Risskov, 
Denmark). The Universal ProbeLibrary probes, likewise used in the qPCR 
experiments, were obtained from Roche Diagnostics (Basel, Switzerland). 
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4.2 Cell Culture (I, II and III) 
 
Human skin fibroblasts (GM08333) were obtained from Coriell Institute for 
Medical Research (Camden, NJ, USA). HeLa cells (ATCC CCL-2, LGC 
Standards) were a kind gift from Dr. Lea Sistonen (Åbo Akademi University, 
Finland). All cells were grown (and treated, unless otherwise stated) in 
Dulbecco’s modified Eagle’s medium, supplemented with 
penicillin/streptomycin, 2 mM L-glutamine and 10% fetal calf serum (Sigma-
Aldrich), at 37°C in a humid environment with 5% CO2.  
 
4.3 Transient transfection of plasmids and siRNA (I and II) 
 
All plasmid transfections were performed using a BIO-RAD Gene Pulser II 
RF Module electroporator. Lipofectamine 2000 (Invitrogen) was used to 
transfect cells with siRNA, according to the manufacturers instructions. 
 
4.4 RNA extraction, reverse transcription and quantitative real time PCR 
analysis (I and II) 
 
Total RNA was isolated from cells using a NucleoSpin RNA II (Macherey-
Nagel, Germany) RNA-extraction kit, according to the manufacturer’s 
instruction. cDNA was obtained through reverse transcription of the purified 
RNA, which was carried out using M-MLV Reverse Transcriptase (Promega, 
Madison, WI, USA). The cDNA was amplified and quantified by performing 
quantitative real time PCR (qPCR). qPCR was performed by the staff at the 
Turku Centre for Biotechnology using the Applied Biosystems 7900 HT Fast 
Sequence Detection System. 
 
4.5 Flow Cytometry and Cell Sorting (II) 
 
The FITC (siRNA) and GFP (GLTP overexpression) positive cells were 
sorted from the untransfected cells to ensure a reliable lipidomics analysis. 
The flow cytometry was performed at the Cell Imaging Core facility at the 
Turku Centre for Biotechnology, Turku, Finland. 
 
4.6 Mass spectrometry analysis (II) 
 
The lipid extraction of the cell samples and the lipidomics analyses were 
conducted by Zora Biosciences Oy (Espoo, Finland) according to their 
standard operating procedures. The species of all phospholipids, SM, DAG 
and CE were analysed by shotgun analysis on a hybrid triple 
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quadrupole/linear ion trap mass spectrometer (QTRAP 5500, AB SCIEX, 
MA) equipped with a robotic nanoflow ion source (NanoMate HD, Advion 
Biosciences, NY). Sphingolipids were analysed by reverse phase ultra-high 
pressure liquid chromatography (UHPLC) using an Acquity BEH C18, 
2.1×50 mm column with a particle size of 1.7 µm (Waters, Milford, MA) 
coupled to a hybrid triple quadrupole/linear ion trap mass spectrometer 
(QTRAP 5500, AB SCIEX, MA). Lipidomic data is based on the analysis of 
each detected lipid class with one technical replicate for each cell sample. The 
samples, the CTRL cells, GLTP siRNA and GLTP OE cells were in 
duplicates.  
 
4.7 Western blot analysis (I and II) 
 
Cells were collected by trypsination, and washed twice in PBS. The pelleted 
cells were redissolved in a lysis buffer (50 mM NaH2PO4, 300 mM NaCl, 10 
mM imidazole, 0.05% Tween-20, 0.5 mM PMSF, 1×Protease inhibitor 
cocktail (Sigma), 1 mM dithiotreithol, pH 8.0). The cells were sonicated 
using a Branson 250 probe sonifier (Emerson Industrial Automation, St. 
Louis, MO, USA), and the lysate protein concentration was determined using 
the method of Lowry [313]. Appropriate amounts of the cell lysates were 
separated on SDS–PAGE and transferred onto a PVDF membrane. 
Immunoblots were labeled using antibodies against GLTP and β-actin. The 
detected proteins were visualized with the ECL chemiluminescence system 
(SuperSignal West Femto, Thermo Scientific) using X-ray film (Fujifilm, 
Tokyo, Japan).  
 
4.8 Synthesis of 3H-labeled ceramides (III) 
 
3H-C6-, 3H*C10-, and 3H-C16-ceramide were prepared from [3-3H]D-erythro-
sphingosine and hexanoic, decanoic and hexadecanoic acids, respectively, 
using N,N'-dicyclohexylcarbodiimide and triethylamine as catalysts [314]. 
[3H]palmitoyl ceramide was prepared from sphingosine and [9-
10,3H]hexadecanoic acid, using N,N'-dicyclohexylcarbodiimide and tri-
ethylamine as catalysts [42]. The products were purified by preparative HPLC 
on a C18 phase, using methanol as solvent. Purity was assessed by analytical 
HPLC, and molecular identity by ESI-MS. 
 
4.9 Preparation of ceramide-cholesterol phosphocholine bilayers (III) 
 
CholPC and ceramide stocks were kept in hexane-isopropanol (3:2 by 
volume) solutions and stored at -20°C until used. Ceramide/CholPC 
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complexes of desired concentration were prepared from the stock solutions. 
The appropriate amount of each lipid was dried under nitrogen in a glass tube, 
redissolved in chloroform to ensure proper lipid mixing and dried again. The 
dehydrated lipid film was hydrated in PBS, pH 7.4, at 55°C for 20 minutes 
and then sonicated for 5 minutes in a FinnSonic M3 bath sonicator (FinnSonic 
Oy, Lahti, Finland) at the same temperature. The solution was further 
sonicated for 10 minutes using a Branson 250 probe sonifier at room 
temperature (Emerson Industrial Automation, St. Louis, MO, USA). The 
resulting clear solution was then immediately centrifuged at 12 000 rpm for 
10 minutes using a tabletop microfuge, to remove titanium probe particles and 
any undispersed lipids. The solution was transferred to a glass tube and kept 
at RT and used within 1 h. Prior to use, the ceramide concentration in the 
solution was re-calculated based on the specific activity of the radiolabeled 
ceramide.  
 
4.10 Metabolic labeling and HPTLC analysis of cellular lipids (I, II and III) 
 
Cells were treated with radioactive lipids as describes in the publications (I – 
III). Following treatment, cell dishes were washed twice with PBS and dried 
to completion in a fume hood. Total lipids were extracted directly from the 
cell dishes using hexane:isopropanol (3:2 by volume). Lipid extracts were 
dried under a stream of nitrogen and redissolved in appropriate volumes of 
hexane:isopropanol. Appropriate volumes of each sample were applied on 
high performance thin-layer chromatography (HPTLC) silica plates 
(Whatman, UK). For GlcCer, GalCer and LacCer separation the solvent 
system chloroform:methanol:acetone:acetic acid:water (10:2:4:2:1) was used. 
For Gb3 separation the solvent system 45:55:10, chloroform:methanol:0.2% 
CaCl2 (in H2O) was used. For phospholipids, chloroform:methanol:acetic 
acid:water; 50:30:8:3 was used as the as the solvent system. The analysis was 
done using standards, run in parallel with the samples. GSL migration was 
visualized using orcinol spray (0.2% orcinol in a 50% H2SO4 solution) and 
heating the plate on 120°C for 5 minutes. Alternatively, iodine staining or 
cupric acid staining was used. The lipid spots were scraped into Optiphase 
‘Hi phase’ scintillation liquid (PerkinElmer-Wallac, Turku, Finland) and the 
radioactivity was measured using a liquid scintillation counter, 1216 Rackbeta 
(PerkinElmer-Wallac, Turku, Finland). After lipid extraction, the total cellular 
proteins were extracted with 0.1 M NaOH and the protein content was 
analysed with the Lowry method [313]. The counts per minute (cpm) 
obtained were either normalized to the total protein content for each 
respective sample, or presented as a percentage of the total signal per sample 
(total cpm in sample lane).  
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4.11 Dot blot analysis of cellular GlcCer and GalCer (III) 
 
High-dose C6- and C10-ceramide (50 µM and 100 µM, respectively) treated 
samples were analysed by HPTLC as described above. The HPTLC plate was 
stained by iodine vapour, and the lipid spots corresponding to C6- and C10-
GlcCer were scraped into glass tubes. The lipids were extracted from the 
scraped silica using chloroform-methanol (2:1 by volume) and dried under a 
nitrogen stream. The dried lipids were redissolved in hexane-isopropanol (3:2 
by volume) and appropriate amounts were dotted onto a nitrocellulose 
membrane, alongside GlcCer and GalCer standards (2 nmol/dot). The lipids 
were visualized by immunoblotting, using commercial rabbit anti-GlcCer and 
rabbit anti-GalCer antibodies (Glycobiotech GmbH), an HRP-conjugated 
anti-rabbit secondary antibody (Thermo Scientific) and enhanced 
chemiluminescence detection (SuperSignal West Femto Maximum Sensitivity 
Substrate, Thermo Scientific).  
 
4.12 Cell viability assay (III) 
 
A resazurin reduction assay (alarmaBlue, Life Technologies) was used to 
investigate cytotoxicity of C6-, C10-, and C16-ceramide. The cells were 
treated for 22 hours with the different ceramides, cholesterol or a PBS-
vehicle. After the 22-hour incubation, the resazurin conversion assay was 
performed according to the manufacturer's instruction. The fluorescence was 
measured by a Varioskan Flash Multimode Reader (Thermo Scientific) using 
an excitation wavelength of 560 nm and an emission wavelength of 590 nm. 
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5. RESULTS AND DISCUSSION 
 
5.1 GLTP expression correlates with cellular GSL synthesis (I and II) 
 
While the structural and membrane-binding properties of GLTP, as well as 
many other of its in vitro capabilities have been studied quite extensively [10, 
226, 260, 261, 266, 271, 315], the biological function of GLTP remains 
elusive. Previous studies have revealed that GLTP, like many other LTPs, is 
localized to the cytosol [256]. In addition to localizing to the cytosol, GLTP 
has been shown to interact with the integral ER membrane protein VAP-A 
[305]. The cellular localization of GLTP is of great importance when 
considering its possible protein interaction partners, as well as which lipids 
would function as its most probable ligands. It has become widely accepted 
that most of the GSLs are synthesized on the luminal side of the Golgi 
apparatus, with the exception of GlcCer, which is produced on the cytosolic 
side [177–182]. Considering its cytosolic nature, the most probable lipid 
substrate for GLTP in vivo is GlcCer, since GLTP would be readily available 
to interact with the lipid at the cytosolic side of the Golgi, immediately after 
its synthesis. Alternatively, GLTP might be able to interact with GlcCer at the 
cytosolic side of the ER (or perhaps the ER/Golgi intermediate compartment), 
following FAPP2-mediated GlcCer translocation [184]. Based on the above-
mentioned findings, we have hypothesized that GLTP might be involved in 
maintaining the cellular glycolipid homeostasis, where GlcCer would be its 
most probable interaction candidate. In an effort to shed light on GLTPs 
biological function, we set out to examine the GLTP-glycolipid connection in 
more detail. 
 
5.1.1 Inhibitors of vesicular transport increase GLTP expression (I) 
 
In the early stages of my thesis work, I observed that treatment of cells with 
the fungal macrolide brefeldin A (BFA) resulted in a several-fold increase in 
GLTP expression. Warnock et al. had previously reported that, while BFA 
treatment effectively inhibited the vesicular transport of lipids and proteins to 
the PM, the transport of GlcCer was retained [310]. The authors postulated 
that, in the absence of vesicular trafficking, GlcCer might be transported by 
non-vesicular means, perhaps with the help of LTPs. Halter and coworkers 
later expanded on the idea and demonstrated the possibility of two glycolipid 
transporting proteins (namely GLTP and FAPP2) being involved in this 
trafficking [184]. These studies promted us to take a closer look at how GLTP 
expression is affected in cells that are treated with BFA and other vesicular 
transport inhibitors, as well as inhibitors of GSL synthesis and degradation. 
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Figure 11. Effects of BFA and monensin treatment on GLTP expression, GLTP 
protein levels and 3H-sphinganine incorporation into GlcCer, GalCer, LacCer, 
ceramide and SM in HSF cells. A) qPCR analysis of GLTP expression in cells treated 
with varying concentrations of BFA (left panel) or monensin (right panel) for 24 
hours. B) qPCR analysis of GLTP expression (filled circles) and HPTLC analysis of 
radiolabeled sphingolipids in cells treated with BFA (0.01 µg/ml, left panel) or 
monensin (5 µg/ml, right panel) for 6, 12 and 24 hours. C) Western blot analysis of 
GLTP levels in cells treated with BFA (0.01 µg/ml) or monensin (5 µg/ml) for 24 
hours. C = untreated control, B = BFA treatment, M = monensin treatment. Beta-actin 
was used as a loading control. Radiolabeling and qPCR results are means +/- SD of at 
least 3 independent experiments. Figure is adapted from publication I. 
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In our studies, we found that a 24-hour treatment of HSF cells with two 
vesicular transport inhibitors (BFA and monensin) resulted in increased 
GLTP mRNA levels (figure 11A), as analysed by qPCR. In the case of 
monensin treatment, the increase in expression was concentration dependent, 
whereas for BFA treatment, the expression peaked rapidly at a low 
concentration. HPTLC and qPCR analysis of cells treated with BFA and 
monensin demonstated a time-dependent increase of GLTP expression and 
3H-sphinganine incorporation into GSLs (figure 11B). The radiolabeling 
results were well in accordance with previous findings [316–319]. Similarly, 
BFA and monensin treatment also increased the total mass of GSLs in cells (I 
– figure 2). The inhibitors also increased the total GLTP levels in cells, as 
assayed by Western blotting (figure 11C). 
 
The two different inhibitors act in different ways regarding how they increase 
radiolabel incorporation into GSLs. BFA inhibits vesicular transfer of 
proteins and lipids to the PM by disrupting vesicle coat assembly and by 
inducing retrograde protein transport from the Golgi apparatus to the ER. This 
subsequently results in the fusion of the two organelles, creating an ER-Golgi 
complex, while leaving the trans-Golgi network fused with the late 
endosomes [320, 321]. The inhibition of vesicular transport presumably leads 
to an accumulation of GSLs in the fused ER-Golgi complex. Monensin is a 
monovalent ionophore that is known to interfere with vesicular transport 
through the Golgi apparatus [319, 322]. Monensin has been shown to inhibit 
the synthesis of SM while increasing radiolabel incorporation into ceramide 
and the GSLs. Our data indicates that the increased synthesis of the various 
GSLs, that results from treatment with these compounds, correlates well with 
the GLTP expression (figure 11B). It is possible that the increased GSL 
synthesis, particularly that of GlcCer, directly results in the cells 
compensating for the increased GSL levels by up-regulating GLTP 
expression. This would support previous suggestions regarding GLTPs 
putative role as a GSL reporter, sensor and/or transporter. 
 
5.1.2 Lysosomal accumulation of GlcCer does not affect GLTP expression (I) 
 
When cells were treated with BFA and monensin, GlcCer demonstrated the 
highest accumulation of the analysed GSLs, both according to absolute 
radiolabeling values (data not shown) as well as based on HPTLC lipid mass 
analysis (I – figure 2). In this study, we did not analyse the radiolabeling or 
mass changes of some of the more complex GSLs (e.g. the globo- and 
ganglio-classes). However, the literature describes the effects that BFA and 
monensin have on higher GSL metabolism fairly comprehensively [168]. In 
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general, the inhibitors severely impede the membrane flow from the proximal 
to the distal Golgi compartments, leading to an immobilization and 
subsequent accumulation of less complex GSLs (such as GlcCer, LacCer and 
GM3), whereas the synthesis of the more complex GSLs is inhibited through 
topological limitation of available precursor lipids [168]. 
 
 
 
 
 
Figure 12. Effect of CBE treatment on GLTP mRNA and protein levels, as well as on 
radiolabel incorporation into sphingolipids. HSF cells were treated with CBE (250 
µM) for 5 days. A) Simple sphingolipid levels were determined by 3H-sphinganine 
incorporation. B) GLTP expression (left) and protein levels (right) as determined by 
qPCR and Western blotting, respectively. Radiolabeling and qPCR results are means 
+/- SD of at least 3 independent experiments. Figure is adapted from publication I. 
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The accumulation of GlcCer in the ER, Golgi and ER/Golgi complex in these 
experiments, could explain the observed increase in GLTP expression. In an 
effort to elucidate whether GLTP expression is affected by de novo synthesis 
of GlcCer in particular, rather than an overall accumulation of this lipid (for 
example as a result of inhibited lysosomal degradation) we used conduritol-
beta-epoxide (CBE). CBE is an inhibitor of beta-glucosidase, an enzyme 
primarily responsible for degradation of GlcCer in the lysosomes [323]. A 5-
day CBE treatment led to a significant increase in radiolabel incorporation 
into GlcCer, as well as an increase of GlcCer mass (figure 12A and I – figure 
4C). However, neither GLTP mRNA nor protein levels were affected by the 
treatment (figure 12B). This suggests that GLTP is more likely to be involved 
in events where GlcCer levels are elevated due to increased synthesis, rather 
than due to inhibited degradation. 
 
5.1.3 Inhibition of GlcCer synthesis decreases GLTP expression (I) 
 
In an effort to further verify that the observed effects were indeed due to an 
increase in de novo GSL synthesis, we utilized two GlcCer synthesis 
inhibitors (n-butyldeoxy-nojirimycin [NB-DNJ] and 1-phenyl-2-decanoyl-
amino-3-morpholino-1-propanol [PDMP]) [324, 325], as well as an inhibitor 
of serine palmitoyl transferase (myriocin) [326]. The assumption was that if 
the BFA- and monensin-mediated increases in de novo GSL synthesis were to 
be impeded by simultaneous exposure to GSL synthesis inhibitors, a 
subsequent decrease in the GLTP expression should also be observable, when 
comparing to the BFA and monensin treatments alone. Figure 13 shows that, 
with the exception of the BFA+NB-DNJ treated cells, all co-treatment 
experiments demonstrated a clear decrease in GLTP expression that seemed 
to correlate well with the inhibited GlcCer radiolabeling. Interestingly, and 
perhaps even paradoxically, both NB-DNJ and PDMP treatment also 
decreased radiolabel incorporation into GalCer. The observation that GalCer 
radiolabeling was not inhibited in the BFA+myriocin treated cells was also 
mystifying. 
 
Treatment with GSL synthesis inhibitors alone also led to decreases GLTP 
expression (I – figure 6). Here, again, treatment with NB-DNJ and PDMP 
decreased GalCer radiolabeling. Interestingly, longer substrate exposure times 
(72 h), using myriocin, were required to observe changes in GLTP protein 
levels. The semi-quantifiable nature of traditional Western blotting may not 
tell the whole story, as minor changes in protein levels are difficult to detect 
on blots. NB-DNJ and PDMP treatment alone also resulted in similarly 
decreased GLTP levels, after 72 hours of treatment (unpublished results). 
Results and Discussion 
 
 55 
 
 
Figure 13. Left panel: Sphingolipid radioactivity (bars) and GLTP mRNA levels 
(filled circles) in HSF cells treated with either BFA alone (0.01 µg/ml), or co-treated 
with BFA and PDMP (50 µM), NB-DNJ (250 µM) or myriocin (25 µM). Right 
panel: Same as left panel, but instead of BFA, monensin was used. 3H-sphinganine 
was used for radiolabeling, with the exception of the myriocin experiments, where 
3H-palmitic acid was used. Radiolabeling and qPCR results are means +/- SD of at 
least 3 independent experiments. Figure is adapted from publication I. 
 
 
Substrates that affect major cellular processes can cause a myriad of 
unpredictable effects on cells. This is a significant methodological limitation 
when attempting to analyse isolated cellular functions, especially in the case 
of BFA and monensin treatment, where the cells are subjected to structural 
changes in the ER and Golgi compartments. While ER stress-induction 
experiments did not seem to alter GLTP expression significantly (I – figure 
10), some of the more unexpected results obtained in this study may be 
explained by possible non-specific effects that the different inhibitors may 
have had on the cells, especially when considering the co-administration 
experiments. Increased specificity regarding alteration of cellular processes 
may be acquired by the use of more direct approaches, such as gene 
regulation by RNA interference. To study the possible GSL-GLTP connection 
more specifically, short-interfering RNA (siRNA) designed to down-regulate 
GlcCerS synthesis was transfected into cells. The expression of the GlcCerS 
gene was down-regulated by approximately 80%, based on qPCR analysis. 
Subsequently, an 80% decrease in GlcCer radiolabeling was also observed, as 
well as a less drastic decrease in GalCer and LacCer radiolabeling (I – figure 
7). Knockdown of GlcCerS also had an effect on GLTP mRNA and protein 
levels, where a clear reduction of both could be observed (I – figure 8). The 
method of GlcCerS down-regulation was further employed in combination 
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with BFA and monensin treatment, where the knockdown of GlcCerS 
expression resulted in decreased GSL synthesis and GLTP expression, even 
in the presence of BFA and monensin (figure 14).  
 
 
 
 
Figure 14. 3H-sphinganine incorporation into GlcCer, GalCer and ceramide (bars) as 
well as GLTP mRNA levels (filled circles) in GlcCerS down-regulated HSF cells, 
treated with BFA (left, 0.01 µg/ml) or with monensin (right, 5 µg/ml). Radiolabeling 
and qPCR results are means +/- SD of at least 3 independent experiments. Figure is 
adapted from publication I. 
 
 
The observation that both the GlcCerS-specific inhibitors PDMP and NB-
DNJ, as well as the specific down-regulation of GlcCerS expression by 
RNAi, markedly reduced GalCer synthesis was unexpected. This raised some 
concern regarding the methodology used in the publication. At first, it was 
assumed that the unexpected results may simply have been due to 
unpredictable secondary reactions that the various inhibitors may have had, 
alone, or particularly, when co-administered. There also exists some 
discrepancy regarding how well different GlcCerS inhibitors actually reduce 
the synthesis of various GSLs [327]. Additionally, while RNA interference 
may be seen as a more direct approach in regulating GlcCer levels, it is not 
without its own problems. GlcCerS is a key enzyme in an important 
metabolic pathway, and its knockdown may have several unpredictable 
effects on the cell. Off-target down-regulation of other genes may also be 
involved. Most important, however, was the possibility that the HPTLC-based 
method was not efficient in separating the endogenous GlcCer and GalCer 
lipid species from each other, and that as a result, contamination between the 
lipid spots could have occurred. Immuno-analysis of the separated spots using 
highly specific anti-GlcCer and anti-GalCer antibodies, however, revealed 
that only minor cross-contamination in the separated lipids spots was 
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detectable (data not shown). In addition, based on the immuno-analysis, it 
became apparent that GlcCer clearly is the major monohexosylceramide 
species in HSF cells. The results indicated that 80 – 90% of the 
monohexosylceramides consisted of GlcCer. Borate-impregnation of HPTLC-
plates, which increases the resolution of GlcCer separation from GalCer 
[328], did not yield differing results from the ones presented in this thesis 
(data not shown). Still, care should be practiced when interpreting the results, 
especially regarding how the GlcCer and GalCer levels correlate to each other 
in the various experiments. 
 
5.1.4 Summarizing notes (I) 
 
Taken together, the results presented in publication I show that there is an 
apparent connection between GSL and GLTP levels in cells. The cells seem 
to up-regulate GLTP expression when there is an increased de novo synthesis 
and/or accumulation of GlcCer at or near its site of synthesis. In contrast, 
when the production of GlcCer is inhibited, GLTP expression is decreased. 
The results support previous suggestions regarding GLTP's possible function 
as a sensor or reporter of GlcCer levels in cells [256, 284]. GlcCerSs have 
been found in a variety of organisms, ranging from animals to plants and 
fungi [164, 165]. Interestingly, some organisms that lack GlcCerS, for 
example Saccharomyces cerevisiae and Schizosaccharomyces pombe, also 
lack GLTP-like proteins [252]. Although this rule is not applicable in all 
cases, there appears to be a fundamental genetic link and co-occurrence 
between GlcCerS and GLTP. 
 
It is tempting to speculate that GLTP may be involved in the transport of 
GlcCer in cells, either directly or indirectly through interaction with other 
lipid transport mechanisms. With the help of its ER-targeting FFAT-like 
motif, GLTP might be able to direct GlcCer away from the ER to other 
cellular destinations, such as the PM, or to the Golgi for further glycosylation. 
As mentioned before, BFA treatment blocks vesicular transport to the PM, 
inhibiting the trafficking of lipids and other cargo. GlcCer, however, seems to 
retain its transport to the PM, despite the absence of a functioning vesicular 
transport system. This non-vesicular transport of GlcCer to the PM has been 
postulated to be protein-mediated [310], and may in part be carried out by 
GLTP [184]. It would seem logical that inhibition of the vesicular transport 
system requires an up-regulation of alternative transport methods for 
maintaining GlcCer transport to the PM, which in turn could explain the up-
regulation of GLTP expression under these conditions.  It is important to note, 
however, that the results presented here do not eliminate the possibility that 
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the observed effects, regarding GLTP mRNA and protein levels, are due to 
changes in other GSLs, such as GalCer or LacCer. 
 
5.1.5 Altering GLTP expression causes changes in the cellular lipidome (II) 
 
In publication I, we examined how alteration of GSL metabolism affects 
GLTP expression and protein levels. In publication II, we instead analysed 
how up- or down-regulation of GLTP levels affect the cellular lipidome. 
Previously, it has been reported that transient up-regulation of GLTP 
expression in HeLa cells led to an increase in radiolabeled GlcCer, whereas a 
transient knockdown of the gltp gene did not result in significant changes in 
GlcCer radiolabeling [256]. In publication II, we expanded upon these 
findings by studying a broader range of lipids, using metabolic labeling and 
HPTLC analysis, complemented by a lipidomics MS approach. Overall, 15 
different lipid classes, including a total of 142 lipid species, were quantified. 
The MS analysis revealed changes in eight lipid species, which presumably 
resulted from either up- or down-regulation of GLTP. These lipids included 
GlcCer, LacCer, Gb3, ceramide, SM, cholesterol-esters (CE), diacylglycerol 
(DAG) and PS.  
 
The two methods of lipid analysis used in publication II differ from each 
other significantly, and these differences should be kept in mind when 
considering the results. The HPTLC data represents all of the chain-specific 
lipids of each particular lipid type analysed, which migrate in close proximity 
to each other on the HPTLC plate (at least when using the solvent systems 
described in section 4.10), and are pooled for subsequent analysis. MS 
methodologies allow for analysis of the various chain-specific lipid species 
separately. When considering the HPTLC data in this study, it should also be 
kept in mind that radiolabel incorporation into lipids does not necessarily 
correspond directly with lipid mass. As such, direct parallels between the MS 
and the HPTLC data should be drawn with caution. Additionally, it should be 
noted that in the MS analysis, GlcCer and GalCer were not distinguishable 
from each other, using the methods described in section 4.6. The HPTLC 
methods were able to separate these lipids for analysis.  
 
5.1.6 GSL levels are affected by changes in GLTP expression (II) 
 
Our results are in accordance with previous findings, where GLTP up-
regulation led to an increase in GlcCer 3H-sphinganine radiolabeling and 
knockdown of GLTP resulted in no significant changes in GlcCer levels 
(figure 15 and 16A) [256]. Differing from previous works, however, were the 
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results that showed an increase in LacCer levels in cells overexpressing 
GLTP, as well as a decrease in cells with down-regulated GLTP synthesis. 
This was apparent from both the MS and HPTLC analysis, however, in the 
radiolabeling experiments the changes were not as pronounced (figure 15 and 
16A). A novel finding was that both up- and down-regulation of GLTP 
caused significant, positive correlation in the cellular Gb3 levels (figure 15 
and 16B). D'Angelo and co-workers have previously demonstrated similar 
effects when silencing FAPP2 expression [183, 249]. In their work, FAPP2 
depletion resulted in decreased LacCer and Gb3 synthesis, while GM3 levels 
remained unchanged. The authors suggest that FAPP2 mediates the transfer 
of GlcCer to distal Golgi compartments, specifically for the subsequent 
synthesis of LacCer and Gb3, but not GM3. These results indicate that at least 
two different LacCer pools exist in the Golgi apparatus, one that is used for 
ganglioside synthesis and another that is used for globoside synthesis. 
Previously, Lingwood et al. have also suggested that neutral and acid GSLs 
are generated from two distinct precursor pools [187]. GlcCer destined for 
LacCer synthesis in the early Golgi is presumably transported by vesicular 
means [183]. 
 
 
 
 
Figure 15. HPTLC analysis of HeLa cells with down- or up-regulated GLTP 
expression. Metabolic labeling of HeLa cells with 3H-sphinganine, control (black), 
GLTP siRNA (red) and overexpression of GLTP (green). Radiolabeling results are 
means +/- SD of at least 3 independent experiments. Figure is adapted from 
publication II. 
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Figure 16. Relative mass changes in lipid species of A) GlcCer/Galcer, LacCer and 
B) Gb3 after knockdown (red) or overexpression (green) of GLTP in HeLa cells, as 
analysed by MS. Black = control. Figure is adapted from publication II. 
 
 
The increase in Gb3 levels that occurs as a result of up-regulating GLTP 
expression could be a direct consequence of the overall increase in GlcCer 
synthesis that also takes place. Controversially, however, down-regulation of 
GLTP in cells does not affect GlcCer levels significantly, whereas Gb3 
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synthesis is still markedly reduced. Previously, FAPP2-ablation has been 
shown to increase GlcCer levels in cells [183, 184]. This is presumably due to 
an accumulation of GlcCer in the earlier compartments along the GSL 
synthesizing membranes, as FAPP2-mediated transport of GlcCer to distal 
Golgi compartments does not occur.  
 
Taken together, the results suggest that FAPP2 and GLTP affect Gb3 
synthesis by different means. Considering that GLTP knockdown does not 
affect GlcCer synthesis significantly, it is possible that GLTP does not 
function as a direct transporter of GlcCer in cells, but rather as a sensor or 
reporter of GlcCer levels. The apparent involvement of both proteins in Gb3-
metabolism also raises the possibility for cellular interaction. Indeed, 
increased levels of GLTP at the ER/early Golgi could lead to an increase in 
the directing or sensing of GlcCer for FAPP2-mediated transport, resulting in 
more GlcCer arriving at the late Golgi compartment for subsequent LacCer 
and Gb3 production. Decreased levels of GLTP would, on the other hand, 
have the opposite effect on Gb3 synthesis. As gangliosides were not analysed 
in this work, their relation to GLTP expression remains unknown. 
 
5.1.7 Alterations in GLTP expression affect the levels of non-GSLs (II) 
 
According to the MS data, the overall ceramide levels were only marginally 
affected by up- or down-regulation of GLTP. Cells overexpressing GLTP 
showed, however, a clear reduction in the d18:0-base ceramides (II – figure 
3E). The MS data also shows that total SM levels were decreased by both 
GLTP overexpression and knowckdown (II – figure 5A). Here, again, a clear 
reduction of d18:0-base SM was observable in the GLTP down-regulated 
samples. Radiolabeling of SM only showed a slight decrease in comparable 
experiments (II – figure 2). SM synthesis is mediated by at least two different 
SM synthases, SMS1 and SMS2 [329]. The SMSs catalyse the exchange of 
phosphocholine from PC to the hydroxyl group of ceramide, yielding SM and 
DAG. SM synthesis is largely dependent of the ceramide transporter CERT, 
which transports ceramide from the ER to the Golgi apparatus [247, 330]. 
Interestingly, CERT is also capable of binding DAG, albeit to a lesser degree 
when compared to ceramide [247, 331]. Still, it has been proposed that CERT 
might transport DAG from the Golgi back to the ER [331]. The MS data 
shows a positive correlation in relation to DAG levels in cells up- or down-
regulating GLTP synthesis (II – figure 4C). The observed changes in the 
DAG levels, as well as those observed in ceramide and SM, may be a 
response caused directly, or indirectly, by the alternation of the cellular GLTP 
activity, either through a disruption of the sphingolipid homeostasis or 
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through a possible interplay between GLTP and CERT. CERT, like GLTP, 
contains a FFAT-like motif which functions to direct the protein to the ER-
compartment by binding to the ER-transmembrane VAPs [300]. Changes in 
cellular ceramide and SM, as well as cholesterol, is not only sensed by CERT, 
but also by OSBP [311]. OSBP, CERT and Nir2 are all proteins that contain 
the FFAT-like motif and are involved in maintaining DAG levels in the Golgi 
[246, 302, 332]. Similarly, GLTP might be involved in the orchestration of 
GSL homeostasis, synergistically, acting in concert with FAPP2 and the other 
FFAT-like motif containing LTPs. 
 
Changes in the PC or PE levels, based on the MS analysis, did not correspond 
well with the radiolabeling experiments (II – figure 2, 5B and 6A). The 
radiolabeling experiments show a significant decrease in both PC and PE 
levels in cells with down-regulated GLTP, whereas up-regulation of GLTP 
expression did not show a significant difference. The MS analysis shows less 
dramatic changes in the overall PC and PE levels, regardless of treatment. 
Such variations might be attributed to the inherent differences between the 
two analysis methods. Based on the MS analysis, cells overexpressing GLTP 
show a significant decrease in PS levels, as well as a marked increase in CE 
levels (II – figure 6B and 4B). Interestingly, the degree of unsaturation in PS 
was also clearly decreased in these cells (II – figure 7D). In mammals, PS is 
synthesized in the ER, where a base-exchange reaction that is catalysed by PS 
synthase-1 (PSS-1) primarily uses PC as a substrate for serine exchange and 
subsequent PS generation [333]. PS synthase-2 (PSS-2) mainly uses PE as a 
substrate. PSS-1 and PSS-2 are both integral ER membrane proteins that 
localize to mitochondria-associated endoplasmic-reticulum subcompartments 
(MAMs), i.e. regions of the ER that closely associate with mitochondria. The 
enzymatic activities required for the synthesis of CE and free cholesterol have 
also been located in the MAM fractions [185]. In addition, GlcCer synthesis 
has been reported to occur, not only in the cis-Golgi [177–182], but also in 
the MAMs [185].  Furthermore, it has been suggested that PS might serve as 
the serine donor in the initial step in the ceramide biosynthesis, where serine 
and palmitoyl coenzyme A are condensed by serine palmitoyl transferase 
[334]. Alteration of GLTP expression might therefore also impact the 
metabolism of these lipid species, considering the above-mentioned synthetic 
pathways and their interconnected status. It is difficult to speculate what the 
reason for the reduction in the degree of unsaturation in PS is, in cells 
overexpressing GLTP. It is possible that these alterations occur in an effort to 
compensate for changes in the membrane packing and fluidity that the 
increased GLTP levels perhaps impart on the cell membranes. 
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5.1.8 Summarizing notes (II) 
 
The cellular lipid metabolism is an intricately complex, interconnected 
system, and the analysis of even a small portion of such a system can be a 
harrowingly difficult task. Overall, while many of the observations presented 
here are quite difficult to interpret, and therefore also difficult to connect to 
possible GLTP activity, the results still offer valuable insights into GLTP and 
its possible cellular function. To summarize, the changes observed are likely 
to be a consequence of GLTP's involvement in binding, sensing or 
transporting GSLs in cells, while working together with the other VAP-
binding LTPs. The changes regarding Gb3 synthesis are of particular interest 
and suggest that there may be a direct interplay between GLTP and FAPP2. 
Analysis of such synergistic functions, between GLTP and different LTPs, are 
therefore of high importance for future projects. It is quite probable that the 
various LTPs act in concert to regulate the overall lipid homeostasis in cells.  
 
5.2 Metabolic conversion of ceramides in cells – a solvent-free delivery 
approach (III) 
 
The HPTLC and MS analysis in publication II presents us with data that 
demonstrated changes, not only in the total masses of some of the different 
lipid species examined, but also in some of the chain-specific lipids. The 
ceramide data, for example, shows a decrease in the d18:0 ceramides as a 
result of GLTP up-regulation, whereas the d18:1 ceramides were overall less 
affected. This was further reflected by a similar decrease in the d18:0 SM 
levels. Similarly, the data show that some GSLs, of certain acyl-chain 
compositions, were affected by the up- or down-regulation of GLTP more 
strongly than others (II – figure 3A – 3D and 4A). Analysis of the more 
chain-specific changes in the cellular lipidome adds a significant level of 
complexity to the issue, but also raises an interesting point regarding GLTP 
and its possible functions. GLTP may have a preference when interacting 
with GSLs of varying acyl-chain compositions. As such, it is also plausible 
that GLTP may have some interaction with the ceramide synthesizing 
enzymes, subsequently affecting which ceramides are being produced. In 
mammals, ceramides are synthesized by six distinct ceramide synthases 
(CerS1-6). Each synthase is responsible for the production of ceramides of 
particular chain lengths [111, 112]. More than 100 distinct, naturally 
occurring ceramides have been identified using current LC-MS/MS 
technology [145]. Additionally, emerging evidence suggests that different 
ceramides, in terms of the length of their N-acyl chains, may be destined to 
perform different cellular functions (see section 2.5.3). 
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The ability to alter how cells produce different chain length sphingolipids 
would be very useful for elucidating whether GLTP, in vivo, shows any 
preference for sphingolipids of particular chain lengths or compositions. 
Although a labour-intensive process, genetic up- or down-regulation of the 
different CerSs is certainly a plausible approach for performing such a task. 
Individual up- and down-regulation of the various CerSs has been performed 
previously, demonstrating complex levels of interregulation and substitutive 
capabilities between the enzymes [335]. However, the simultaneous genetic 
alteration of more than one CerS rapidly increases the complexity of the 
matter. Alternative methodological approaches, for analysing what roles the 
different chain length ceramides play in cells, would therefore be welcome. 
Natural ceramides are molecules that exhibit very poor solubility water, and 
therefore cannot be effectively introduced to cells by dispersion into aqueous 
growth media. As a consequence, studies where ceramides have been 
introduced to cultured cells have primarily made use of DMSO or ethanol 
dispersions of the more water-soluble, non-physiological, short-chain 
ceramide variants [21, 336, 337]. Such studies have helped establish the 
ceramides as key players in the cellular apoptotic pathways, as well as several 
other cellular processes [145]. The short-chain ceramides, and the effects they 
impart on cells, may not fully reflect those of their endogenous counterparts. 
The role of endogenous ceramide has previously been investigated through 
the manipulation of the various enzymes involved in ceramide metabolism, 
such as the SMases [338, 339]. Even so, a method for introducing longer-
chain, physiological ceramides to cells would be very useful in elucidating the 
possible roles of the different ceramide species more precisely. 
 
Lönnfors et al. previously showed that C6- and C16-ceramide (figure 17) can 
form stable bilayers with cholesteryl phosphocholine (CholPC), in an 
equimolar ratio [312]. Ceramide and cholesterol do not react favourably in the 
absence of phospholipids with large polar headgroups, however, when 
ceramide is complexed with CholPC, the phosphocholine headgroup acts to 
protect the ceramide from the aqueous environment and allows for the 
formation of lipid bilayer vesicles. Similarly, CholPC can form complexes 
with cholesterol and dimyristoglycerol [312]. Furthermore, Sukumaran and 
co-workers demonstrated that complexes of CholPC and C6-ceramide could 
be used to deliver ceramide to cells in culture. Using this delivery method, the 
inhibition of cell proliferation was reportedly more drastic, when compared to 
formulations of C6-ceramide and DMSO [340]. In publication III, we set out 
to expand upon this methodology and to test whether longer-chain ceramides 
could successfully be introduced to cells in CholPC complexes. 
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Figure 17. Molecular structures of the different chain length ceramides and CholPC 
used in this study. Figure is from publication III. 
 
 
5.2.1 The rate of ceramide uptake depends on the acyl chain length (III) 
 
Initially, we tested whether cells were able to take up C10- and C16-ceramide 
from the growth medium, when the ceramides were complexed with CholPC 
in an equimolar ratio. We compared the rates of radiolabel uptake, to that of 
the already established uptake of C6-ceramide from similar complexes [340]. 
In the experiments described below, the radionuclide resided on the 
sphingosine base of the ceramide, unless otherwise stated. We found that all 
three ceramide/CholPC complexes demonstrated successful ceramide delivery 
to HeLa cells, when the cells were exposed to growth medium containing 50 
µM of the respective ceramides in complex (figure 18A).  
 
C6-ceramide had the highest uptake rate, followed by C10-ceramide and C16-
ceramide. C10-ceramide demonstrated an initial uptake rate of roughly 50% 
to that of C6-ceramide, whereas C16-ceramide similarly only demonstrated a 
5% uptake rate. For C6- and C10-ceramide treated cells, radiolabel uptake 
seemed to plateau within 6 hours from the beginning of the experiment. To 
test for equipotent delivery, ceramide uptake was analysed using two different 
concentrations for each ceramide. Radiolabel uptake seemed to directly 
correlate with the ceramide concentration in the growth medium, 
demonstrating an equipotent delivery, at least within the concentrations and 
timeframe used (figure 18B). 
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Figure 18. A) The amounts of radiolabeled C6-, C10- and C16-ceramide uptake as 
nmol/mg cellular protein, as a function of time. HeLa cells were labeled with 
radioactive ceramide (50 µM), with the radionuclide in positions 4 and 5 of the 
sphingosine backbone. The uptake was analysed by HPTLC and scintillation 
counting. B) Amounts of ceramide precursor incorporation into HeLa cells at 
different loading concentrations of ceramides after a 3-hour incubation. Results are 
means +/- SEM of at least 3 independent experiments. Figure is from publication III. 
 
 
5.2.2 Ceramide metabolism depends on the ceramide uptake rate (III) 
 
Once the cellular uptake had been established, we decided to take a closer 
look at how the different ceramides were metabolised by the cells. Cells were 
treated with 50 µM of each respective ceramide for 3, 6 and 24 hours, 
whereafter total lipids were extracted from the cells and the radiolabel 
distribution was analysed. The results show that the incorporated ceramides 
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are metabolised and that the radiolabel is distributed into other sphingolipids 
as a function of time (III – figure 3). It is interesting to note that in the C6-
ceramide treated cells, a large portion of the radioactivity could be found in 
the simple GSLs (i.e. the pooled GlcCer, GalCer and Glc/GalCer-OH), at the 
24-hour mark (III – figure 3A). In contrast, in both the C10- and C16-
ceramide treated cells, most of the radioactive signal could be found in SM, 
after 24 hours of treatment (III – figure 3B and 3C). Chapman et al. 
previously showed that cancerous cells in culture convert C6-ceramide to 
either SM or GlcCer, in a manner depending on the initial concentration of 
ceramide used in the growth medium [341]. In lower-dose treatments, cancer 
cells seem to favour conversion of C6-ceramide to SM, whereas higher-dose 
treatments result in conversion to GlcCer. Glycosylation may perhaps be a 
general survival mechanism, by which cells dispose of unnaturally high 
amounts of ceramide. Indeed, it has been previously shown that when 
ceramides are co-administered with GlcCer synthase inhibitors, as well as P-
glycoprotein antagonists, ceramide-induced apoptosis increases [341–343]. 
Presumably, as glycosylation is inhibited, the higher accumulation of 
ceramide leads to a more drastic anti-proliferative effect. 
 
Since, in our experiments, the various ceramides demonstrated different rates 
of cellular uptake (figure 18), we next decided to test whether metabolic 
conversion, similar to what observable in the C6-ceramide treated cells (III – 
figure 3A), was attainable with the longer-chain C10- and C16-ceramides. By 
increasing the concentrations of the C10- and C16-ceramide complexes in the 
culture medium, we hoped to simulate the effects observed in the C6-
ceramide experiments. HeLa cells were exposed to varying concentrations of 
the respective ceramides for 24 hours, whereafter the radiolabel distribution 
into the cellular lipids was analysed as described above. This time, however, a 
more in-depth analysis of the radiolabel distribution was performed (figure 
19 and 20). Suitable ceramide concentrations were estimated based on the 
incoporation rates in figure 18, and from previous works in the literature 
[341]. 
 
In these experiments, lower-dose treatment with C6-ceramide (1 µM) resulted 
in most of the radioactive signal to be found in SM, whereas the higher-dose 
treatments (25 – 100 µM) demonstrated strong signals in C6-GlcCer (figure 
19A). Similar results were observed for the C10-ceramide treated cells 
(figure 19B), where a clear glycosylation of C10-ceramide was observable in 
cells treated with 100 µM of the lipid. Interestingly, glycosylation was not as 
pronounced in cells treated with 200 µM of C10-ceramide. 
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Figure 19. Metabolic conversion of (A) C6- and (B) C10-ceramide by HeLa cells at 
various concentrations. The ceramides were [3H]-labeled in the sphingosine. After 24 
hours of ceramide uptake the total lipids were extracted and analysed by HPTLC and 
scintillation counting. “Start” and “Front” refer to the labeled lipids remaining on the 
application spot, or being eluted along with the solvent front, “Other” refers to the 
traces of radiolabeled lipids between the identified spots on the HPTLC plate (see III 
– supplemental figure 1). Results are means +/- SEM of at least 3 independent 
experiments. Figure is from publication III. 
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Figure 20. Metabolic conversion of C16-ceramide at various concentrations. The 
C16-ceramide was either [3H]-labeled in the sphingosine backbone (A) or in the 
palmitic acid portion (B). After 24 hours of treatment, the total lipids were extracted 
and analysed by HPTLC and scintillation counting. “Start” and “Front” refer to the 
labeled lipids remaining on the application spot, or being eluted along the solvent 
front, “Other” refers to the traces of radiolabeled lipids between the identified spots 
on the HPTLC plate (see III – supplemental figure 1). Results are means +/- SEM of 
at least 3 independent experiments. Figure is from publication III. 
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For C16-ceramide, both a sphingosine 3H-labeled and a palmitic acid 3H-
labeled ceramide was used, in separate experiments (figure 20). In these 
experiments, higher-dose (100 – 200 µM) treatments with C16-ceramide did 
not show a marked increase in GSL radioactivity. Instead, large portions of 
the radioactive signal remained as ceramide. This was evident for both the 
sphingosine 3H-labeled and the palmitic acid 3H-labeled C16-ceramide. In the 
experiments where the radiolabel resided on the acyl chain of the ceramide, a 
significant portion of the radioactivity was distributed to the glycero-
phospholipids, especially in the lower-dose experiments (figure 20B). This 
suggests that the externally introduced C16-ceramide is subject to significant 
degradation, at least under the conditions used in publication III.  
 
5.2.3 Externally introduced C16-ceramide is mainly degraded (III) 
 
In an attempt to clarify how C16-ceramide is metabolised, we investigated 
whether inhibition of ceramide degradation using the lysosomal inhibitor 
chloroquine [344], as well as the ceramidase inhibitor ceranib-2 [345], could 
be used to inhibit the supposed degradation of the introduced C16-ceramide. 
When the palmitic acid 3H-labeled C16-ceramide (50 µM) was introduced to 
cells in the presence of these substrates, a substantial reduction in glycero-
phospholipid radioactivity could be observed (III – figure S2). Based on these 
observations, it seems likely that the signal observed in SM in figure 20A 
would similarly be due to the recycling of the sphingosine base, as a result of 
ceramide degradation. This assumption was further put to the test, when we 
investigated whether the ceramide synthase inhibitor fumonisin B1 [346] 
could be used to inhibit the incorporation of the putatively liberated 
sphingosine into SM (III – figure S3). The results show that a significant 
reduction in SM radioactivity is achieved when cells are simultaneously 
treated with 200 µM fumonisin B1 and 50 µM sphingosine 3H-labeled C16-
ceramide. These results support the assumption that C16-ceramide is mainly 
degraded when introduced to cells in the manners described, and that this 
degradation, at least partly, takes place in the lysosome. However, neither of 
the inhibitors resulted in complete suppression of ceramide degradation and 
one cannot therefore rule out that some of the signal observed in SM (and the 
GSLs) came from directly modified ceramide. In fact, the act of using 
inhibitors may in itself result in the cell up-regulating the use of the externally 
delivered ceramides for direct synthesis of higher sphingolipids. Indeed, the 
chloroquine-mediated inhibition of lysosomal degradation also led to a 
increase in SM radiolabeling, suggesting that the C16-ceramide may have 
more readily been used for direct SM synthesis (III – figure S2). 
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Figure 21. A) A representative HPTLC plate analysis of lipid extracts from HeLa 
cells treated with high doses of ceramide (50 µM C6-ceramide, 100 µM C10-
ceramide and 200 µM C16-ceramide). The image illustrates the separation of GlcCer 
with incorporated chain specific ceramides (C6 or C10) from endogenous GSLs. The 
plate was stained with orcinol to detect the carbohydrate groups of the GSLs. B) A 
dot blot analysis was performed to verify that the lipid spots observed in the high-
dose C6- and C10-ceramide treatments were GlcCer. The C6- and C10-GlcCer spots 
were scraped off an iodine stained HPTLC plate, extracted from the silica and 
analysed using anti-GlcCer and anti-GalCer antibodies. Figure is adapted from 
publication III. 
 
 
Whether or not a similar recycling of the 3H-labeled sphingosine base was 
observed in the C6- and C10-ceramide treated cells, is not discernible from 
the experiments presented in publication III. However, since endogenous 
GlcCer and GalCer also showed a marked increase in the high-dose C6-
ceramide treated cells (figure 19A), it can be presumed that at least some 
recycling takes place. This assumption is supported by previous research, 
where it was shown that C6-ceramide loading of A549 adenocarcinoma 
epithelial cells leads to higher synthesis of endogenous ceramide, due to 
recycling of the sphingosine backbone, but not due to elongation of the short 
acyl chain [347]. It is interesting to note that high-dose treatment with C6- 
and C10-ceramide shows an accumulation of radioactivity in C6- and C10-
GlcCer. Neither LacCer (contained within the “other” spot), to which GlcCer 
is a direct synthetic precursor, nor any of the higher GSLs (contained within 
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the “TLC start” spot) showed any marked increases in radioactivity in 
response to the treatments (figure 19A and 19B). This suggests that C6- and 
C10-GlcCer are not further glycosylated to form higher GSLs. It is worth 
noting that in the respective high-dose treatment experiments, the C6-GlcCer 
and C10-GlcCer spots were visually clearly discernible from the endogenous 
GlcCer and GalCer on orcinol-stained HPTLC plates, whereas C16-GlcCer 
was not (figure 21A). It can, therefore, be assumed that the radioactivity 
present in the C6-GlcCer and C10-GlcCer spots accurately represents GlcCer 
that has been directly glycosylated from C6- and C10-ceramide, respectively. 
To verify the lipid identity of these spots, C6-GlcCer and C10-GlcCer were 
validated by immunoblotting, using rabbit anti-GlcCer and anti-GalCer 
antibodies (figure 21B).  
 
5.2.4 The different ceramides exhibit varying degrees of anti-proliferative 
effects (III) 
 
The apoptotic effects that ceramides have on cells are evident. External 
apoptotic stimuli have been found to increase ceramide levels in cells and 
exogenous treatment with short-chain ceramide has been shown to cause cells 
to undergo apoptosis [21, 23, 24, 348]. Ceramide has been implicated in both 
the extrinsic and the intrinsic apoptotic signaling pathways. The methods of 
action include inhibition of the PI 3-kinase/Akt pathway as well as the 
permeabilization of the mitochondrial outer membranes [129, 130, 349–352]. 
  
As previously reported, cells treaded with C6-ceramide that had been 
complexed to CholPC in vesicles, demonstrated more dramatic apoptotic 
effects and inhibition of cell growth, when compared to cells treated with 
DMSO-solubilized ceramide [340]. In publication III, the respective lower-
dose ceramide treatments did not result in noticeable cell-detachment, 
whereas higher-dose treatments did. Therefore, to establish the degree of 
inhibition the different complexes had on cell proliferation, we performed a 
resazurin-conversion assay on cells treated with increasing concentrations (25 
– 200 µM, 24 hours) of the various ceramides and respective cholesterol-
CholPC controls. Resazurin is a redox indicator that yields a colorimetric 
change and a fluorescent signal in response to cellular metabolic activity, 
when added to cells in culture [353]. A decrease in these signals can be 
directly correlated with loss of cell viability. The cell viability in each sample 
was normalized to PBS-vehicle treated controls (figure 22). C6-ceramide was 
the most potent in decreasing cell viability, followed by C10- and C16-
ceramide. This was perhaps not unexpected, considering the rates of cellular 
uptake that the different ceramides previously demonstrated (figure 18).  
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Figure 22. Cytotoxic effects of the various ceramides. HeLa cells were treated with 
increasing concentrations of C6-, C10-, C16-ceramide or cholesterol, complexed with 
CholPC, for 22 h and compared to vehicle (PBS) treated cells. Subsequently, a 
resazurin reduction assay was performed. Viability of the HeLa cells is represented as 
percentage of survival compared to the PBS control. Results are means +/- SEM of at 
least 3 independent experiments. Figure is from publication III. 
 
 
Based on these results, it seems as if C6-ceramide has an intrinsically stronger 
anti-proliferative effect, when compared to C10-ceramide. C6-ceramide 
demonstrated more efficient inhibition of cell viability, even when the molar 
uptake of C10-ceramide was higher than that of C6-ceramide (25 µM C6-
ceramide treatment vs. 100 µM C10-ceramide treatment, figure 18B and 22). 
Furthermore, it is interesting to note that treatment with 200 µM C16-
ceramide led to a comparable inhibition of cell viability to that of a 100 µM 
treatment with C10-ceramide (figure 22), even though the initial rate of C16-
ceramide incorporation at these conditions was less than half of that of C10-
ceramide (figure 18B). One explanation to this phenomenon may lie in how 
the cells metabolise, or rather, how the cells do not metabolise C16-ceramide, 
when the lipid is presented at high concentrations. As the concentration of 
C16-ceramide in the culture medium was increased, more of the radioactive 
signal remained as ceramide, presumably due to a decrease in the degradation 
and the subsequent recycling of the radiolabel (figure 20). As a result, the 
increased cellular ceramide concentration might have lead to stronger anti-
proliferative effects. Alternatively, while a high-dose treatment with 
cholesterol and CholPC (200 µM) did not affect cell viability to a significant 
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degree, one cannot exclude the possibility that simultaneously high levels of 
ceramide and CholPC may result in combinational effects, which alter how 
the ceramides are metabolised in cells. It is possible that such a combinational 
effect might result in the inhibition of ceramide glycosylation and/or 
degradation. As noted previously, when C10-ceramide was complexed with 
CholPC and presented to cells at a concentration of 200 µM, subsequent 
glycosylation to C10-GlcCer was significantly decreased, when compared to 
the corresponding 100 µM treatment (figure 19B). The literature does 
describe similar inhibitory effects on sphingolipid synthesis, which can be 
attributed to increased cholesterol levels in cells. The loading of HSF cells 
with cholesterol, with the help of cyclodextrin-inclusion complexes, has 
previously been shown to decrease the de novo synthesis of both ceramide 
and SM [354]. However, since CholPC is structurally different from naturally 
occurring cholesterol, the results in publication III are not necessarily 
comparable, and parallels should be drawn with caution. 
 
5.2.5 Summarizing notes (III) 
 
Overall, the results from publication III present us with a valid, solvent-free 
method of introducing ceramides to cultured cells. The ceramides are taken 
up at rates that correspond with their acyl chain lengths, where shorter lipids 
are internalized more quickly than their longer-chain counterparts. C6-
ceramide seems to have an intrinsically stronger anti-proliferative effect when 
compared to C10-ceramide. Higher-dose treatment of HeLa cells with C6- 
and C10-ceramide resulted in glycosylation of the ceramide, which produced 
corresponding chain length GlcCer. C16-ceramide was mainly degraded 
when introduced to cells at lower doses and its metabolisation was reduced at 
higher doses. Since the degree of ceramide glycosylation seems to be linked 
to the rate of ceramide uptake, the overall slower incorporation speed of the 
C16-ceramide was perhaps not enough to trigger a noticeable glycosylation. 
Whether or not similar glycosylation of longer-chain ceramides is attainable 
at sufficient internalization rates is something that warrants further 
exploration. 
 
5.4 Future prospects (I, II and III) 
 
From publications I and II, it is fairly evident that GLTP is biologically 
connected to the GSLs. Furthermore, the discovery that GLTP expression 
correlates with levels of cellular GlcCer and Gb3, opens up interesting 
viewpoints regarding the protein's function. As previously mentioned, these 
results raise the possibility for the existence of a cellular connection between 
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GLTP and FAPP2. Down-regulation of FAPP2 leads to an accumulation of 
GlcCer that is comparable to the decrease in the levels of LacCer and Gb3 in 
cells [184, 249], whereas GLTP knockdown does not significantly alter 
GlcCer synthesis (figure 15, 16A and [256]). Furthermore, the ablation of 
FAPP2 has a more dramatic effect on Gb3 levels, when compared to GLTP 
knockdown (~50% reduction vs. ~25% reduction, respectively). Taken 
together, these results suggest that GLTP and FAPP2 carry out distinct 
functions regarding Gb3 synthesis, although one should be mindful of the 
possibility that the observed differences in Gb3 reduction may be due to 
methodological variations. There is evidence suggesting that FAPP2 acts as a 
bona fide transporter of GlcCer in cells [183, 249], whereas the results 
presented here, and in previous works, may be more indicative of a sensory 
role for GLTP [256]. It is also clear that neither GLTP nor FAPP2 is 
indispensable when it comes to Gb3 synthesis, suggesting that the proteins 
may compensate for the lack of each other. If (and how) the two proteins 
come together to regulate Gb3 synthesis is clearly something that warrants 
further research. While the generation of double knockout GLTP- and 
FAPP2-mutants has previously been unsuccessful [184], unpublished results 
from our laboratory demonstrate that transient down-regulation of both 
proteins simultaneously in cultured cells is indeed possible. Consequently, 
this allows for the analysis of whether or not GLTP and FAPP2 are involved 
in compensatory functions, and possibly whether these proteins interact in 
cells. Furthermore, the utilization of fluorescence microscopy-based analysis, 
such as bimolecular fluorescence complementation (BiFC) [355], could 
demonstrate the plausibility of a GLTP-FAPP2 in vivo interaction. Indeed, we 
have recently demonstrated that cellular interaction between the ER-residing 
VAP-A and GLTP occurs, using BiFC-microscopy (unpublished results). 
 
The MS results from publication II suggest that GLTP might be involved in 
the synthesis of lipids of particular chain lengths and compositions. However, 
these details are difficult to interpret, since modulation of GLTP expression 
seemingly affects the prevalence of certain acyl chain compositions, not just 
in the GSLs, but in non-sphingolipids as well. Nevertheless, of the analysed 
chain-specific Gb3s, all species positively correlate with GLTP expression 
(figure 16B), with the biggest difference occurring in the 18:0 and 24:1 acyl-
chain Gb3 species, in cells overexpressing GLTP. These particular Gb3 
species might function as a good starting point for further experiments, if one 
were to hypothesize that GLTP is somehow involved in the cellular regulation 
of GSLs of particular acyl-chain compositions. The selective alteration of the 
expression of the various CerSs could possibly be a good method for 
elucidating this putative GLTP-lipid specificity. Subsequently, adapting the 
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methodology presented in publication III for similar analysis could likewise 
be plausible. At the present, study of the chain-specific binding and transfer 
of GSLs by GLTP is already being carried out in our laboratory, using SPR- 
and FRET-based in vitro assays. 
 
The method by which ceramide is internalized from the CholPC complexes is 
unknown. Sukumaran and coworkers previously suggested that C6-ceramide 
uptake mainly takes place by monomer exchange between the complexes and 
the PM [340]. Indeed, since the ceramide/CholPC vesicles likely need to exist 
in equimolar complexes for maximal stability, some sort of lipid replacement 
must occur, as the ceramides are internalized. No lipid precipitate was 
observable in the reaction medium in any of the experiments performed in 
publication III, as evidenced by routine microscopy analysis, suggesting that 
little or no complex collapse occurred due to shifts in vesicular CholPC-to-
lipid molar ratios. Since the longer-chain ceramides in publication III are 
taken up at markedly diminished rates, and since the acyl-chain length of 
lipids have been shown to correlate with their transfer efficiency between 
membranes [356, 357], monomer exchange presumably remains the most 
likely scenario of ceramide uptake. However, some degree of endocytic 
internalization cannot be ruled out, as it was previously observed that CholPC 
was also internalized from the complexes (albeit to a minor degree) [340]. By 
extension, it would be interesting to study what kind of lipids the CholPC 
complexes putatively replace in the membrane as the ceramides are taken up 
by the cells. Subsequently, the method might be adapted as a simple tool for 
analysing the ceramide and/or cholesterol content in the PM of cultured cells.  
 
GLTP expression has previously been linked to the prevalence of short-chain 
ceramide in cells [358]. Zou and coworkers showed that when HeLa cells 
were incubated with C6-ceramide, an Sp1/Sp3 transcription factor-mediated 
activation of the GLTP promoter was induced. Interestingly enough, short-
chain C8-GlcCer did not result in similar results. The authors hypothesized 
that the externally introduced ceramide would subsequently result in an 
increased GLTP promoter activation in one of two ways: either by altering 
Sp1/Sp3 binding affinity or by altering Sp3 acetylation status. A ceramide-
induced acetylation of Sp3 has previously been shown to regulate the 
transcriptional activity of human telomerase reverse transcriptase [359]. 
Furthermore, the promoter activity of GlcCerS has also been shown to 
increase in response to ceramide treatment [360], which is in agreement with 
the results shown in publication III, regarding the increased endogenous 
GlcCer synthesis as well as the glycosylation of C6-ceramide (figure 19A). 
Preliminary experiments from our laboratory show that GLTP levels are 
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indeed affected by the introduction of short-chain C6-ceramides, however, the 
results seem somewhat contradictory to those which were reported by Zou 
and coworkers [358]. Our results show that both C6-ceramide and C8-GlcCer 
result in a clear reduction of endogenous GLTP levels within 24 hours of 
treatment (figure 23). 
 
 
 
 
 
 
 
 
 
 
Figure 23. GLTP levels in HeLa (left) and HSF (right) cells treated with DMSO-
solubilized C6-ceramide (C6, 25 µM) or C8-GlcCer (G8, 30 µM) for 24 hours, as 
determined by Western blotting. C = untreated vehicle controls. Beta-actin was used 
as a loading control. Unpublished results. 
 
 
It should be noted, however, that mRNA expression does not necessarily 
correlate positively with the total corresponding protein levels in cells. 
Additionally, Zou and co-workers did not analyse GLTP mRNA or promoter 
activity past 12 hours of ceramide treatment, whereas the results presented in 
figure 23 are from a 24-hour treatment. It is interesting to speculate why 
GLTP levels would be reduced as a result of these treatments. The effect is 
likely to be linked to the glycosylation events observed in these cells, as both 
C6-ceramide and C8-GlcCer result in a similar reduction of GLTP levels. As 
mentioned in section 5.2.3, very little of the glycosylated short-chain 
ceramide is further metabolised to produce higher GSLs. Therefore, there 
must be an accumulation of short-chain GlcCer at some compartment in the 
cell. This accumulation may act to “block” GLTP from interacting with 
natural GlcCer, subsequently leading to a decreased production (or perhaps to 
an increased degradation) of GLTP. It is possible that the unnatural chain 
length GlcCer cannot be sensed or transported by GLTP in vivo, perhaps due 
to improper packing into membranes or due to its intrinsically more rapid 
membrane lateral movement. In the future, it would be interesting to test what 
effects longer-chain ceramides might have on GLTP, by adapting the method 
from publication III to deliver natural ceramides to cells, at rates sufficient 
enough to putatively induce glycosylation. In its present form, however, the 
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method may be not be suitable for this purpose. As the chain length of the 
complexed ceramide is increased, the subsequent rate of uptake decreases. 
While this can, to some extent, be corrected for by simply adding more of the 
complexed ceramide to the growth medium, there is presumably a limit to 
how high one can go. As the results from publication III suggest, cells may be 
subjected to unexpected combinational effects, arising from simultaneously 
high levels of ceramide and CholPC. Therefore, the method may have to be 
developed and studied more extensively, if one were to use it for analysis 
using longer-chain ceramides (e.g. 24:1). One possible way by which an 
increased uptake might be achieved is the simultaneous addition of a lipid-
transferring substrate to the growth medium, such as purified, recombinant 
CERT. Similar experiments have already demonstrated functionality; 
recombinant GLTP has been shown to successfully extract GSLs from the 
PM of cells [184], and could presumably likewise be used to transfer GSLs 
from donor membranes to cultured cells [361]. 
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6. CONCLUSIONS 
 
As a whole, the work described in this thesis explores the metabolism and 
function of sphingolipids. In particular, their relationship to GLTP is 
examined, in an effort to uncover hints toward the protein’s cellular function.  
 
Overall, the previous postulations regarding GLTP's function are 
strengthened. GLTP has been suggested to function as a carrier or sensor of 
GSLs, based on structural analysis, as well as model and cellular experiments. 
In our work, we show that GLTP expression correlates positively with 
changes in cellular GSL levels, particularly with GlcCer. More specifically, 
GLTP expression seems to correlate with the levels of de novo synthesized 
GlcCer, suggesting that GLTP might perform a function at, or close to, the 
site of GlcCer synthesis. Furthermore, the finding that Gb3 synthesis is 
affected by changes in cellular GLTP levels suggests that GLTP may have a 
similar function to FAPP2, which is likewise involved in the synthesis of 
Gb3. By extension, it is plausible that GLTP and FAPP2 might interact and 
work together to maintain the cellular GSL homeostasis. This interaction 
could putatively take place at the ER, where both proteins perhaps interact 
with the ER-resident membrane protein VAP-A, through their FFAT-like 
motives. The results also suggest that alteration of cellular GLTP expression 
induces changes in the levels of lipids of certain acyl-chain compositions. As 
such, it is possible that GLTP might be involved in cellular events that 
employ GSLs of specific acyl-chain compositions. 
 
In publication III, we set out to examine a novel method of introducing 
various chain length ceramides to cells, in the hopes that this method could 
eventually be utilized in a more complete mapping of ceramide function. The 
results show that complexation with CholPC offers a viable method for 
solubilizing ceramides of various chain lengths in aqueous solutions and, 
furthermore, that the ceramides are taken up, and metabolised, when 
presented to cells in culture. Based on the results, C6-ceramide seems to have 
an intrinsically stronger anti-proliferative effect when compared to C10-
ceramide. Interestingly, it was also observed that when short-chain ceramides 
were introduced to cells at sufficient rates, their metabolism shifted towards 
GlcCer synthesis. We were not able to observe similar conversion of C16-
ceramide, possibly due to the significantly slower uptake of this lipid from the 
CholPC complexes. The reasons behind the glycosylation, and whether or not 
naturally occurring, longer-chain ceramides also undergo such conversion 
when presented to cells at sufficient rates, are interesting questions that 
should be addressed in future studies. 
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